<td class='article_abstract' colspan='2'>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
a	DT	a
lysosomal	JJ	lysosomal
storage	NN	storage
disorder	NN	disorder
caused	VBN	cause
by	IN	by
a	DT	a
deficiency	NN	deficiency
of	IN	of
the	DT	the
enzyme	NN	enzyme
acid	NN	acid
alpha-glucosidase	NN	<unknown>
.	SENT	.
Patients	NNS	patient
have	VBP	have
skeletal	JJ	skeletal
muscle	NN	muscle
and	CC	and
respiratory	JJ	respiratory
<span class='symptom'>
weakness	NN	weakness
</span>
with	IN	with
or	CC	or
without	IN	without
<span class='symptom'>
cardiomyopathy	NN	<unknown>
</span>
.	SENT	.
The	DT	the
objective	NN	objective
of	IN	of
our	PP$	our
review	NN	review
was	VBD	be
to	TO	to
systematically	RB	systematically
evaluate	VB	evaluate
the	DT	the
quality	NN	quality
of	IN	of
evidence	NN	evidence
from	IN	from
the	DT	the
literature	NN	literature
to	TO	to
formulate	VB	formulate
evidence-based	JJ	<unknown>
guidelines	NNS	guideline
for	IN	for
the	DT	the
diagnosis	NN	diagnosis
and	CC	and
management	NN	management
of	IN	of
patients	NNS	patient
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
The	DT	the
literature	NN	literature
review	NN	review
was	VBD	be
conducted	VBN	conduct
using	VBG	use
published	VBN	publish
literature	NN	literature
,	,	,
clinical	JJ	clinical
trials	NNS	trial
,	,	,
cohort	NN	cohort
studies	NNS	study
and	CC	and
systematic	JJ	systematic
reviews	NNS	review
.	SENT	.
Cardinal	NP	Cardinal
treatment	NN	treatment
decisions	NNS	decision
produced	VBD	produce
seven	CD	seven
management	NN	management
guidelines	NNS	guideline
and	CC	and
were	VBD	be
assigned	VBN	assign
a	DT	a
GRADE	NP	Grade
classification	NN	classification
based	VBN	base
on	IN	on
the	DT	the
quality	NN	quality
of	IN	of
evidence	NN	evidence
in	IN	in
the	DT	the
published	VBN	publish
literature	NN	literature
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
six	CD	six
recommendations	NNS	recommendation
were	VBD	be
made	VBN	make
based	VBN	base
on	IN	on
best	JJS	good
clinical	JJ	clinical
practices	NNS	practice
but	CC	but
with	IN	with
insufficient	JJ	insufficient
data	NNS	datum
to	TO	to
form	VB	form
a	DT	a
guideline	NN	guideline
.	SENT	.
Studying	VBG	study
outcomes	NNS	outcome
in	IN	in
rare	JJ	rare
diseases	NNS	disease
is	VBZ	be
challenging	VBG	challenge
due	JJ	due
to	TO	to
the	DT	the
small	JJ	small
number	NN	number
of	IN	of
patients	NNS	patient
,	,	,
but	CC	but
this	DT	this
is	VBZ	be
in	RB	in
particular	JJ	particular
the	DT	the
reason	NN	reason
why	WRB	why
we	PP	we
believe	VBP	believe
that	IN	that
informed	JJ	informed
treatment	NN	treatment
decisions	NNS	decision
need	VBP	need
to	TO	to
consider	VB	consider
the	DT	the
quality	NN	quality
of	IN	of
the	DT	the
evidence	NN	evidence
.	SENT	.
</td>
<td class='article_abstract' colspan='2'>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
a	DT	a
fatal	JJ	fatal
genetic	JJ	genetic
muscle	NN	muscle
disorder	NN	disorder
caused	VBN	cause
by	IN	by
a	DT	a
deficiency	NN	deficiency
of	IN	of
acid	JJ	acid
α-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
,	,	,
a	DT	a
glycogen-degrading	JJ	<unknown>
lysosomal	JJ	lysosomal
enzyme	NN	enzyme
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
the	DT	the
human	JJ	human
<span class='gene'>
GAA	NP	<unknown>
</span>
cDNA	NN	<unknown>
gene	NN	gene
was	VBD	be
synthesized	VBN	synthesize
from	IN	from
human	JJ	human
placenta	NN	placenta
cells	NNS	cell
and	CC	and
cloned	VBN	clon
into	IN	into
a	DT	a
plant	NN	plant
expression	NN	expression
vector	NN	vector
under	IN	under
the	DT	the
control	NN	control
of	IN	of
the	DT	the
rice	NN	rice
α-amylase	NN	<unknown>
3D	JJ	3D
(	(	(
RAmy3D	NP	<unknown>
)	)	)
promoter	NN	promoter
.	SENT	.
The	DT	the
plant	NN	plant
expression	NN	expression
vector	NN	vector
was	VBD	be
introduced	VBN	introduce
into	IN	into
rice	NN	rice
calli	NNS	<unknown>
(	(	(
Oryza	NP	<unknown>
sativa	NP	<unknown>
L.	NP	L.
cv	NP	Cv
.	SENT	.
Dongjin	NP	<unknown>
)	)	)
mediated	VBD	mediate
by	IN	by
Agrobacterium	NN	<unknown>
tumefaciens	NNS	<unknown>
.	SENT	.
Genomic	NP	<unknown>
DNA	NP	DNA
PCR	NP	PCR
and	CC	and
Northern	NP	Northern
blot	NN	blot
analysis	NN	analysis
were	VBD	be
used	VBN	use
to	TO	to
determine	VB	determine
the	DT	the
integration	NN	integration
and	CC	and
mRNA	NN	<unknown>
expression	NN	expression
of	IN	of
the	DT	the
hGAA	NN	<unknown>
gene	NN	gene
in	IN	in
the	DT	the
putative	JJ	putative
transgenic	JJ	transgenic
rice	NN	rice
cells	NNS	cell
.	SENT	.
SDS-PAGE	NP	<unknown>
and	CC	and
Western	NP	Western
blot	NN	blot
analysis	NN	analysis
showed	VBD	show
that	IN	that
the	DT	the
glycosylated	JJ	<unknown>
precursor	NN	precursor
recombinant	JJ	recombinant
hGAA	NN	<unknown>
had	VBD	have
a	DT	a
molecular	JJ	molecular
mass	NN	mass
of	IN	of
110kDa	NP	<unknown>
due	JJ	due
to	TO	to
the	DT	the
presence	NN	presence
of	IN	of
seven	CD	seven
N-glycosylation	NN	<unknown>
sites	NNS	site
.	SENT	.
The	DT	the
accumulation	NN	accumulation
of	IN	of
hGAA	NN	<unknown>
protein	NN	protein
in	IN	in
the	DT	the
culture	NN	culture
medium	NN	medium
was	VBD	be
approximately	RB	approximately
37mg/L	JJ	<unknown>
after	IN	after
11	CD	@card@
days	NNS	day
of	IN	of
culturing	VBG	culture
in	IN	in
a	DT	a
sugar	NN	sugar
depletion	NN	depletion
medium	NN	medium
.	SENT	.
The	DT	the
His	PP$	his
tagged-hGAA	NN	<unknown>
protein	NN	protein
was	VBD	be
purified	VBN	purify
using	VBG	use
an	DT	an
Ni-NTA	NP	<unknown>
column	NN	column
and	CC	and
confirmed	VBD	confirm
as	IN	as
the	DT	the
precursor	NN	precursor
form	NN	form
of	IN	of
hGAA	NN	<unknown>
without	IN	without
the	DT	the
signal	NN	signal
peptide	NN	peptide
encoded	VBN	encode
by	IN	by
the	DT	the
cDNA	NN	<unknown>
on	IN	on
the	DT	the
N-terminal	JJ	<unknown>
amino	NN	amino
acid	NN	acid
sequence	NN	sequence
.	SENT	.
The	DT	the
acid	JJ	acid
alpha-glucosidase	NN	<unknown>
activity	NN	activity
of	IN	of
hGAA	NN	<unknown>
produced	VBN	produce
in	IN	in
transgenic	JJ	transgenic
rice	NN	rice
cells	NNS	cell
gave	VBD	give
results	NNS	result
similar	JJ	similar
to	TO	to
those	DT	those
of	IN	of
the	DT	the
enzyme	NN	enzyme
produced	VBN	produce
by	IN	by
CHO	NP	Cho
cells	NNS	cell
.	SENT	.
</td>
<td class='article_abstract' colspan='2'>
Previous	JJ	previous
reports	NNS	report
suggest	VBP	suggest
that	IN	that
although	IN	although
a	DT	a
diagnostic	JJ	diagnostic
muscle	NN	muscle
biopsy	NN	biopsy
can	MD	can
confirm	VB	confirm
the	DT	the
presence	NN	presence
of	IN	of
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
the	DT	the
absence	NN	absence
of	IN	of
a	DT	a
definitive	JJ	definitive
biopsy	NN	biopsy
result	NN	result
does	VBZ	do
not	RB	not
rule	VB	rule
out	RP	out
the	DT	the
diagnosis.In	NN	<unknown>
this	DT	this
study	NN	study
,	,	,
we	PP	we
reviewed	VBD	review
patients	NNS	patient
with	IN	with
a	DT	a
limb-girdle	NN	<unknown>
syndrome	NN	syndrome
who	WP	who
demonstrated	VBD	demonstrate
nonspecific	JJ	<unknown>
abnormalities	NNS	abnormality
of	IN	of
muscle	NN	muscle
,	,	,
without	IN	without
evidence	NN	evidence
of	IN	of
the	DT	the
classical	JJ	classical
changes	NNS	change
of	IN	of
acid	JJ	acid
maltase	NN	maltase
deficiency	NN	deficiency
.	SENT	.
These	DT	these
patients	NNS	patient
were	VBD	be
rescreened	VBN	<unknown>
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
using	VBG	use
dried	VBN	dry
blood	NN	blood
spot	NN	spot
(	(	(
DBS	NP	DBS
)	)	)
testing.Twenty-seven	JJ	<unknown>
patients	NNS	patient
provided	VBD	provide
blood	NN	blood
samples	NNS	sample
for	IN	for
the	DT	the
DBS	NP	DBS
test	NN	test
.	SENT	.
Four	CD	Four
patients	NNS	patient
underwent	VBD	undergo
subsequent	JJ	subsequent
genetic	JJ	genetic
testing	NN	testing
.	SENT	.
Genetic	JJ	genetic
analysis	NN	analysis
demonstrated	VBD	demonstrate
that	IN	that
one	CD	one
patient	NN	patient
tested	VBD	test
positive	JJ	positive
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
and	CC	and
one	CD	one
patient	NN	patient
had	VBD	have
one	CD	one
copy	NN	copy
of	IN	of
a	DT	a
pathogenic	JJ	pathogenic
variant.In	NN	<unknown>
conclusion	NN	conclusion
,	,	,
the	DT	the
ability	NN	ability
of	IN	of
a	DT	a
diagnostic	JJ	diagnostic
muscle	NN	muscle
biopsy	NN	biopsy
to	TO	to
definitively	RB	definitively
rule	VB	rule
out	RP	out
the	DT	the
presence	NN	presence
of	IN	of
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
is	VBZ	be
limited	VBN	limit
.	SENT	.
There	EX	there
is	VBZ	be
a	DT	a
role	NN	role
for	IN	for
a	DT	a
screening	VBG	screen
DBS	NP	DBS
in	IN	in
all	DT	all
patients	NNS	patient
presenting	VBG	present
with	IN	with
a	DT	a
limb-girdle	NN	<unknown>
syndrome	NN	syndrome
without	IN	without
a	DT	a
clear	JJ	clear
diagnosis	NN	diagnosis
.	SENT	.
</td>
<td class='article_abstract' colspan='2'>
The	DT	the
article	NN	article
provides	VBZ	provide
an	DT	an
overview	NN	overview
of	IN	of
advances	NNS	advance
in	IN	in
the	DT	the
induced	VBN	induce
pluripotent	JJ	<unknown>
stem	NN	stem
cell	NN	cell
field	NN	field
to	TO	to
model	NN	model
cardiomyopathies	NNS	<unknown>
of	IN	of
inherited	VBN	inherit
inborn	JJ	inborn
errors	NNS	error
of	IN	of
metabolism	NN	metabolism
and	CC	and
acquired	VBD	acquire
metabolic	JJ	metabolic
syndromes	NNS	syndrome
in	IN	in
vitro.Several	JJ	<unknown>
inborn	JJ	inborn
errors	NNS	error
of	IN	of
metabolism	NN	metabolism
have	VBP	have
been	VBN	be
studied	VBN	study
using	VBG	use
'	''	'
disease	NN	disease
in	IN	in
a	DT	a
dish	NN	dish
'	POS	'
models	NNS	model
,	,	,
including	VBG	include
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
<span class='disease'>
Danon	NP	<unknown>
disease	NN	disease
</span>
,	,	,
<span class='disease'>
Fabry	NP	Fabry
disease	NN	disease
</span>
,	,	,
and	CC	and
<span class='disease'>
Barth	NP	Barth
syndrome	NN	syndrome
</span>
.	SENT	.
Disease	NN	disease
phenotypes	NNS	phenotype
of	IN	of
complex	JJ	complex
metabolic	JJ	metabolic
syndromes	NNS	syndrome
,	,	,
such	JJ	such
as	IN	as
<span class='symptom'>
diabetes	NN	diabetes
mellitus	NN	<unknown>
</span>
and	CC	and
aldehyde	NN	aldehyde
dehydrogenase	NN	dehydrogenase
2	CD	2
deficiency	NN	deficiency
,	,	,
have	VBP	have
also	RB	also
been	VBN	be
observed.Differentiation	NN	<unknown>
of	IN	of
patient	NN	patient
and	CC	and
disease-specific	JJ	<unknown>
induced	VBN	induce
pluripotent	NN	<unknown>
stem	VBP	stem
cell-derived	JJ	<unknown>
cardiomyocytes	NNS	<unknown>
has	VBZ	have
provided	VBN	provide
the	DT	the
capacity	NN	capacity
to	TO	to
model	VB	model
deleterious	JJ	deleterious
cardiometabolic	JJ	<unknown>
diseases	NNS	disease
to	TO	to
understand	VB	understand
molecular	JJ	molecular
mechanisms	NNS	mechanism
,	,	,
perform	VB	perform
drug	NN	drug
screens	NNS	screen
,	,	,
and	CC	and
identify	VB	identify
novel	NN	novel
drug	NN	drug
targets.⚫	JJ	<unknown>
</td>
<td class='article_abstract' colspan='2'>
Enzyme	NP	<unknown>
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
with	IN	with
recombinant	JJ	recombinant
human	JJ	human
(	(	(
rh	NN	<unknown>
)	)	)
acid	NN	acid
α-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
has	VBZ	have
prolonged	VBN	prolong
the	DT	the
survival	NN	survival
of	IN	of
patients	NNS	patient
.	SENT	.
However	RB	however
,	,	,
the	DT	the
paucity	NN	paucity
of	IN	of
cation-independent	JJ	<unknown>
mannose-6-phosphate	NN	<unknown>
receptor	NN	receptor
(	(	(
CI-MPR	NP	<unknown>
)	)	)
in	IN	in
skeletal	JJ	skeletal
muscle	NN	muscle
,	,	,
where	WRB	where
it	PP	it
is	VBZ	be
needed	VBN	need
to	TO	to
take	VB	take
up	RP	up
rhGAA	NN	<unknown>
,	,	,
correlated	VBN	correlate
with	IN	with
a	DT	a
poor	JJ	poor
response	NN	response
to	TO	to
ERT	NN	ERT
by	IN	by
muscle	NN	muscle
in	IN	in
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
Clenbuterol	NP	<unknown>
,	,	,
a	DT	a
selective	JJ	selective
β2	JJ	<unknown>
receptor	NN	receptor
agonist	NN	agonist
,	,	,
enhanced	VBD	enhance
the	DT	the
CI-MPR	NP	<unknown>
expression	NN	expression
in	IN	in
striated	VBN	striate
muscle	NN	muscle
through	IN	through
Igf-1	NP	<unknown>
mediated	VBD	mediate
<span class='symptom'>
muscle	NN	muscle
hypertrophy	NN	hypertrophy
</span>
,	,	,
which	WDT	which
correlated	VBD	correlate
with	IN	with
increased	VBN	increase
CI-MPR	NP	<unknown>
(	(	(
also	RB	also
the	DT	the
Igf-2	NP	<unknown>
receptor	NN	receptor
)	)	)
expression	NN	expression
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
we	PP	we
have	VBP	have
evaluated	VBN	evaluate
4	CD	4
new	JJ	new
drugs	NNS	drug
in	IN	in
<span class='gene'>
GAA	NP	<unknown>
</span>
knockout	NN	knockout
(	(	(
KO	NP	KO
)	)	)
mice	NNS	mouse
in	IN	in
combination	NN	combination
with	IN	with
an	DT	an
adeno-associated	JJ	<unknown>
virus	NN	virus
(	(	(
AAV	NP	<unknown>
)	)	)
vector	NN	vector
encoding	VBG	encode
human	JJ	human
<span class='gene'>
GAA	NP	<unknown>
</span>
,	,	,
3	CD	3
alternative	JJ	alternative
β2	JJ	<unknown>
agonists	NNS	agonist
and	CC	and
dehydroepiandrosterone	NN	<unknown>
(DHEA)	NN	<unknown>
.	SENT	.
Mice	NNS	mouse
were	VBD	be
injected	VBN	inject
with	IN	with
AAV2/9-CBhGAA	NP	<unknown>
(	(	(
1E+11	JJ	<unknown>
vector	NN	vector
particles	NNS	particle
)	)	)
at	IN	at
a	DT	a
dose	NN	dose
that	WDT	that
was	VBD	be
not	RB	not
effective	JJ	effective
at	IN	at
clearing	VBG	clear
glycogen	NN	glycogen
storage	NN	storage
from	IN	from
the	DT	the
heart	NN	heart
.	SENT	.
Heart	NP	Heart
<span class='gene'>
GAA	NP	<unknown>
</span>
activity	NN	activity
was	VBD	be
significantly	RB	significantly
increased	VBN	increase
by	IN	by
either	DT	either
salmeterol	NN	<unknown>
(	(	(
p<0.01	JJ	<unknown>
)	)	)
or	CC	or
DHEA	NP	<unknown>
(	(	(
p<0.05	NN	<unknown>
)	)	)
,	,	,
in	IN	in
comparison	NN	comparison
with	IN	with
untreated	JJ	untreated
mice	NNS	mouse
.	SENT	.
Furthermore	RB	furthermore
,	,	,
glycogen	NN	glycogen
content	NN	content
was	VBD	be
reduced	VBN	reduce
in	IN	in
the	DT	the
heart	NN	heart
by	IN	by
treatment	NN	treatment
with	IN	with
DHEA	NP	<unknown>
(	(	(
p<0.001	JJ	<unknown>
)	)	)
,	,	,
salmeterol	NN	<unknown>
(	(	(
p<0.05	NN	<unknown>
)	)	)
,	,	,
formoterol	NN	<unknown>
(	(	(
p<0.01	JJ	<unknown>
)	)	)
,	,	,
or	CC	or
clenbuterol	NN	<unknown>
(	(	(
p<0.01	JJ	<unknown>
)	)	)
in	IN	in
combination	NN	combination
with	IN	with
the	DT	the
AAV	NP	<unknown>
vector	NN	vector
,	,	,
in	IN	in
comparison	NN	comparison
with	IN	with
untreated	JJ	untreated
GAA-KO	NP	<unknown>
mice	NNS	mouse
.	SENT	.
Wirehang	NP	<unknown>
testing	NN	testing
revealed	VBD	reveal
that	IN	that
salmeterol	NN	<unknown>
and	CC	and
the	DT	the
AAV	NP	<unknown>
vector	NN	vector
significantly	RB	significantly
increased	VBN	increase
performance	NN	performance
,	,	,
in	IN	in
comparison	NN	comparison
with	IN	with
the	DT	the
AAV	NP	<unknown>
vector	NN	vector
alone	RB	alone
(p<0.001)	JJ	<unknown>
.	SENT	.
Similarly	RB	similarly
,	,	,
salmeterol	NN	<unknown>
with	IN	with
the	DT	the
vector	NN	vector
increased	VBD	increase
performance	NN	performance
significantly	RB	significantly
more	RBR	more
than	IN	than
any	DT	any
of	IN	of
the	DT	the
other	JJ	other
drugs	NNS	drug
.	SENT	.
The	DT	the
most	RBS	most
effective	JJ	effective
individual	JJ	individual
drugs	NNS	drug
had	VBD	have
no	DT	no
significant	JJ	significant
effect	NN	effect
in	IN	in
absence	NN	absence
of	IN	of
vector	NN	vector
,	,	,
in	IN	in
comparison	NN	comparison
with	IN	with
untreated	JJ	untreated
mice	NNS	mouse
.	SENT	.
Thus	RB	thus
,	,	,
salmeterol	NN	<unknown>
should	MD	should
be	VB	be
further	RBR	further
developed	VBN	develop
as	IN	as
adjunctive	JJ	adjunctive
therapy	NN	therapy
in	IN	in
combination	NN	combination
with	IN	with
either	DT	either
ERT	NN	ERT
or	CC	or
gene	NN	gene
therapy	NN	therapy
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
</td>
<td class='article_abstract' colspan='2'>
Patients	NNS	patient
with	IN	with
late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
develop	VB	develop
progressive	JJ	progressive
hypercapnic	JJ	<unknown>
<span class='symptom'>
respiratory	JJ	respiratory
failure	NN	failure
</span>
that	WDT	that
can	MD	can
be	VB	be
disproportionate	JJ	disproportionate
to	TO	to
the	DT	the
respiratory	JJ	respiratory
muscle	NN	muscle
compromise	NN	compromise
and/or	CC	and/or
thoracic	JJ	thoracic
restriction	NN	restriction
.	SENT	.
Although	IN	although
recent	JJ	recent
studies	NNS	study
have	VBP	have
reported	VBN	report
the	DT	the
presence	NN	presence
of	IN	of
a	DT	a
blunted	VBN	blunt
hypercapnic	JJ	<unknown>
respiratory	JJ	respiratory
response	NN	response
in	IN	in
some	DT	some
subjects	NNS	subject
with	IN	with
neuromuscular	JJ	neuromuscular
disorders	NNS	disorder
and	CC	and
chronic	JJ	chronic
<span class='symptom'>
hypercapnia	NN	<unknown>
</span>
,	,	,
no	DT	no
study	NN	study
has	VBZ	have
evaluated	VBN	evaluate
the	DT	the
integrity	NN	integrity
of	IN	of
the	DT	the
respiratory	JJ	respiratory
drive	NN	drive
in	IN	in
subjects	NNS	subject
with	IN	with
late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
.	SENT	.
Thus	RB	thus
,	,	,
we	PP	we
endeavor	VBP	endeavor
to	TO	to
determine	VB	determine
the	DT	the
CO2	NP	<unknown>
rebreathing	NN	<unknown>
response	NN	response
in	IN	in
subjects	NNS	subject
with	IN	with
late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
.Respiratory	JJ	<unknown>
muscle	NN	muscle
strength	NN	strength
was	VBD	be
assessed	VBN	assess
by	IN	by
measuring	VBG	measure
the	DT	the
maximum	JJ	maximum
inspiratory	JJ	inspiratory
pressure	NN	pressure
,	,	,
and	CC	and
the	DT	the
maximum	JJ	maximum
expiratory	JJ	expiratory
pressure	NN	pressure
.	SENT	.
The	DT	the
maximum	JJ	maximum
inspiratory	JJ	inspiratory
pressure	NN	pressure
reflects	VBZ	reflect
the	DT	the
strength	NN	strength
of	IN	of
the	DT	the
diaphragm	NN	diaphragm
and	CC	and
other	JJ	other
inspiratory	JJ	inspiratory
muscles	NNS	muscle
,	,	,
whereas	IN	whereas
the	DT	the
maximum	JJ	maximum
expiratory	JJ	expiratory
pressure	NN	pressure
reflects	VBZ	reflect
the	DT	the
strength	NN	strength
of	IN	of
the	DT	the
abdominal	JJ	abdominal
muscles	NNS	muscle
and	CC	and
other	JJ	other
expiratory	JJ	expiratory
muscles	NNS	muscle
.	SENT	.
We	PP	we
studied	VBD	study
the	DT	the
hypercapnic	JJ	<unknown>
drive	NN	drive
response	NN	response
(	(	(
measured	VBN	measure
as	IN	as
the	DT	the
ratio	NN	ratio
of	IN	of
the	DT	the
change	NN	change
in	IN	in
airway-occlusion	NN	<unknown>
pressure	NN	pressure
0.1	CD	@card@
s	NNS	<unknown>
after	IN	after
the	DT	the
start	NN	start
of	IN	of
inspiration	NN	inspiration
and	CC	and
end-tidal	JJ	<unknown>
PCO2	NN	<unknown>
in	IN	in
13	CD	@card@
subjects	NNS	subject
with	IN	with
late-onset	NN	late-onset
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
and	CC	and
51	CD	@card@
healthy	JJ	healthy
controls.Overall	NN	<unknown>
inspiratory	JJ	inspiratory
muscle	NN	muscle
strength	NN	strength
was	VBD	be
within	IN	within
normal	JJ	normal
limits	NNS	limit
or	CC	or
slightly	RB	slightly
diminished	VBN	diminish
in	IN	in
the	DT	the
late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
group	NN	group
.	SENT	.
Five	CD	Five
subjects	NNS	subject
(	(	(
38.5	CD	@card@
%	NN	%
)	)	)
were	VBD	be
chronically	RB	chronically
hypercapnic	JJ	<unknown>
,	,	,
and	CC	and
9	CD	9
(	(	(
69.2	CD	@card@
%	NN	%
)	)	)
had	VBD	have
an	DT	an
increased	VBN	increase
breath-holding	NN	<unknown>
time	NN	time
.	SENT	.
Compared	VBN	compare
with	IN	with
controls	NNS	control
,	,	,
the	DT	the
change	NN	change
in	IN	in
airway-occlusion	NN	<unknown>
pressure	NN	pressure
0.1	CD	@card@
s/change	NN	<unknown>
in	IN	in
end-tidal	JJ	<unknown>
CO2	NP	<unknown>
pressure	NN	pressure
slope	NN	slope
(	(	(
hypercapnic	JJ	<unknown>
respiratory	JJ	respiratory
drive	NN	drive
)	)	)
was	VBD	be
lower	JJR	low
in	IN	in
the	DT	the
late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
group	NN	group
(	(	(
median	NN	median
0.050	CD	@card@
[	SYM	[
interquartile	JJ	<unknown>
range	NN	range
0.027-0.118	CD	@card@
]	SYM	]
vs	NP	vs
0.183	CD	@card@
[	SYM	[
0.153-0.233	CD	@card@
]	SYM	]
,	,	,
P	NN	P
<	SYM	<
.001)	JJ	<unknown>
.	SENT	.
Nine	CD	Nine
subjects	NNS	subject
(	(	(
69.2	CD	@card@
%	NN	%
)	)	)
had	VBD	have
a	DT	a
blunted	VBN	blunt
change	NN	change
in	IN	in
airway-occlusion	NN	<unknown>
pressure	NN	pressure
0.1	CD	@card@
s/change	NN	<unknown>
in	IN	in
end-tidal	JJ	<unknown>
carbon	NN	carbon
dioxide	NN	dioxide
pressure	NN	pressure
slope.Subjects	NNS	<unknown>
with	IN	with
late-onset	NN	late-onset
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
had	VBD	have
an	DT	an
impaired	JJ	impaired
hypercapnic	JJ	<unknown>
respiratory	JJ	respiratory
drive	NN	drive
response	NN	response
.	SENT	.
The	DT	the
clinical	JJ	clinical
<span class='gene'>
impact	NN	impact
</span>
of	IN	of
this	DT	this
phenomenon	NN	phenomenon
in	IN	in
this	DT	this
subject	JJ	subject
subset	NN	subset
deserves	VBZ	deserve
further	RBR	further
investigation.⚫	JJ	<unknown>
</td>
<td class='article_abstract' colspan='2'>
Diagnosis	NN	diagnosis
of	IN	of
neuromuscular	JJ	neuromuscular
diseases	NNS	disease
in	IN	in
primary	JJ	primary
care	NN	care
is	VBZ	be
often	RB	often
challenging	VBG	challenge
.	SENT	.
Rare	JJ	rare
diseases	NNS	disease
such	JJ	such
as	IN	as
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
are	VBP	be
easily	RB	easily
overlooked	VBN	overlook
by	IN	by
the	DT	the
general	JJ	general
practitioner	NN	practitioner
.	SENT	.
We	PP	we
therefore	RB	therefore
aimed	VBD	aim
to	TO	to
develop	VB	develop
a	DT	a
diagnostic	JJ	diagnostic
support	NN	support
tool	NN	tool
using	VBG	use
patient-oriented	JJ	patient-oriented
questions	NNS	question
and	CC	and
combined	JJ	combined
data	NNS	datum
mining	VBG	mine
algorithms	NNS	algorithm
recognizing	VBG	recognize
answer	NN	answer
patterns	NNS	pattern
in	IN	in
individuals	NNS	individual
with	IN	with
selected	JJ	selected
neuromuscular	JJ	neuromuscular
diseases	NNS	disease
.	SENT	.
A	DT	a
multicenter	NN	multicenter
prospective	JJ	prospective
study	NN	study
for	IN	for
the	DT	the
proof	NN	proof
of	IN	of
concept	NN	concept
was	VBD	be
conducted	VBN	conduct
thereafter.First	RB	<unknown>
,	,	,
16	CD	@card@
interviews	NNS	interview
with	IN	with
patients	NNS	patient
were	VBD	be
conducted	VBN	conduct
focusing	VBG	focus
on	IN	on
their	PP$	their
pre-diagnostic	JJ	<unknown>
observations	NNS	observation
and	CC	and
experiences	NNS	experience
.	SENT	.
From	IN	from
these	DT	these
interviews	NNS	interview
,	,	,
we	PP	we
developed	VBD	develop
a	DT	a
questionnaire	NN	questionnaire
with	IN	with
46	CD	@card@
items	NNS	item
.	SENT	.
Then	RB	then
,	,	,
patients	NNS	patient
with	IN	with
diagnosed	VBN	diagnose
neuromuscular	JJ	neuromuscular
diseases	NNS	disease
as	RB	as
well	RB	well
as	IN	as
patients	NNS	patient
without	IN	without
such	PDT	such
a	DT	a
disease	NN	disease
answered	VBD	answer
the	DT	the
questionnaire	NN	questionnaire
to	TO	to
establish	VB	establish
a	DT	a
database	NN	database
for	IN	for
data	NN	data
mining	NN	mining
.	SENT	.
For	IN	for
proof	NN	proof
of	IN	of
concept	NN	concept
,	,	,
initially	RB	initially
only	RB	only
six	CD	six
diagnoses	NNS	diagnosis
were	VBD	be
chosen	VBN	choose
(	(	(
myotonic	JJ	myotonic
dystrophy	NN	dystrophy
and	CC	and
<span class='symptom'>
myotonia	NN	myotonia
</span>
(	(	(
MdMy	NP	<unknown>
)	)	)
,	,	,
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
(	(	(
MP	NN	MP
)	)	)
,	,	,
<span class='disease'>
amyotrophic	JJ	<unknown>
lateral	JJ	lateral
sclerosis	NN	sclerosis
</span>
(	(	(
<span class='disease'>
ALS	NP	<unknown>
</span>
)	)	)
,	,	,
<span class='symptom'>
polyneuropathy	NN	<unknown>
</span>
(	(	(
<span class='gene'>
PNP	NP	<unknown>
</span>
)	)	)
,	,	,
<span class='symptom'>
spinal	JJ	spinal
muscular	JJ	muscular
atrophy	NN	atrophy
</span>
(	(	(
<span class='disease'>
SMA	NP	<unknown>
</span>
)	)	)
,	,	,
other	JJ	other
neuromuscular	JJ	neuromuscular
diseases	NNS	disease
,	,	,
and	CC	and
no	DT	no
neuromuscular	JJ	neuromuscular
disease	NN	disease
(NND)	NN	<unknown>
.	SENT	.
A	DT	a
prospective	JJ	prospective
study	NN	study
was	VBD	be
performed	VBN	perform
to	TO	to
validate	VB	validate
the	DT	the
automated	JJ	automated
malleable	JJ	malleable
system	NN	system
,	,	,
which	WDT	which
included	VBD	include
six	CD	six
different	JJ	different
classification	NN	classification
methods	NNS	method
combined	VBN	combine
in	IN	in
a	DT	a
fusion	NN	fusion
algorithm	NN	algorithm
proposing	VBG	propose
a	DT	a
final	JJ	final
diagnosis	NN	diagnosis
.	SENT	.
Finally	RB	finally
,	,	,
new	JJ	new
diagnoses	NNS	diagnosis
were	VBD	be
incorporated	VBN	incorporate
into	IN	into
the	DT	the
system.In	NN	<unknown>
total	NN	total
,	,	,
questionnaires	NNS	questionnaire
from	IN	from
210	CD	@card@
individuals	NNS	individual
were	VBD	be
used	VBN	use
to	TO	to
train	VB	train
the	DT	the
system	NN	system
.	SENT	.
89.5	CD	@card@
%	NN	%
correct	JJ	correct
diagnoses	NNS	diagnosis
were	VBD	be
achieved	VBN	achieve
during	IN	during
cross-validation	JJ	cross-validation
.	SENT	.
The	DT	the
sensitivity	NN	sensitivity
of	IN	of
the	DT	the
system	NN	system
was	VBD	be
93-97	CD	@card@
%	NN	%
for	IN	for
individuals	NNS	individual
with	IN	with
MP	NN	MP
,	,	,
with	IN	with
MdMy	NP	<unknown>
and	CC	and
without	IN	without
neuromuscular	JJ	neuromuscular
diseases	NNS	disease
,	,	,
but	CC	but
only	RB	only
69	CD	@card@
%	NN	%
in	IN	in
<span class='disease'>
SMA	NP	<unknown>
</span>
and	CC	and
81	CD	@card@
%	NN	%
in	IN	in
<span class='disease'>
ALS	JJ	<unknown>
</span>
patients	NNS	patient
.	SENT	.
In	IN	in
the	DT	the
prospective	JJ	prospective
trial	NN	trial
,	,	,
57/64	CD	@card@
(	(	(
89	CD	@card@
%	NN	%
)	)	)
diagnoses	NNS	diagnosis
were	VBD	be
predicted	VBN	predict
correctly	RB	correctly
by	IN	by
the	DT	the
computerized	JJ	computerized
system	NN	system
.	SENT	.
All	DT	all
questions	NNS	question
,	,	,
or	CC	or
rather	RB	rather
all	DT	all
answers	NNS	answer
,	,	,
increased	VBD	increase
the	DT	the
diagnostic	JJ	diagnostic
accuracy	NN	accuracy
of	IN	of
the	DT	the
system	NN	system
,	,	,
with	IN	with
the	DT	the
best	JJS	good
results	NNS	result
reached	VBN	reach
by	IN	by
the	DT	the
fusion	NN	fusion
of	IN	of
different	JJ	different
classifier	NN	classifier
methods	NNS	method
.	SENT	.
Receiver	NN	receiver
operating	VBG	operate
curve	NN	curve
(	(	(
ROC	NP	<unknown>
)	)	)
and	CC	and
p-value	NN	<unknown>
analyses	NNS	analysis
confirmed	VBD	confirm
the	DT	the
results.A	NN	<unknown>
questionnaire-based	JJ	<unknown>
diagnostic	JJ	diagnostic
support	NN	support
tool	NN	tool
using	VBG	use
data	NN	data
mining	NN	mining
methods	NNS	method
exhibited	VBD	exhibit
good	JJ	good
results	NNS	result
in	IN	in
predicting	VBG	predict
selected	JJ	selected
neuromuscular	JJ	neuromuscular
diseases	NNS	disease
.	SENT	.
Due	JJ	due
to	TO	to
the	DT	the
variety	NN	variety
of	IN	of
neuromuscular	JJ	neuromuscular
diseases	NNS	disease
,	,	,
additional	JJ	additional
studies	NNS	study
are	VBP	be
required	VBN	require
to	TO	to
measure	VB	measure
beneficial	JJ	beneficial
effects	NNS	effect
in	IN	in
the	DT	the
clinical	JJ	clinical
setting.⚫	JJ	<unknown>
</td>
<td class='article_abstract' colspan='2'>
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
(	(	(
OMIM	NP	<unknown>
no	RB	no
232300	CD	@card@
)	)	)
is	VBZ	be
an	DT	an
autosomal	JJ	autosomal
recessive	NN	recessive
inherited	VBD	inherit
metabolic	JJ	metabolic
disorder	NN	disorder
,	,	,
caused	VBN	cause
by	IN	by
glycogen	NN	glycogen
accumulation	NN	accumulation
in	IN	in
the	DT	the
lysosome	NN	lysosome
due	JJ	due
to	TO	to
deficiency	NN	deficiency
of	IN	of
the	DT	the
lysosomal	JJ	lysosomal
acid	JJ	acid
03B1-glucosidase	NN	<unknown>
enzyme	NN	enzyme
.	SENT	.
Here	RB	here
we	PP	we
report	VBP	report
the	DT	the
case	NN	case
of	IN	of
an	DT	an
8-month-old	JJ	<unknown>
girl	NN	girl
of	IN	of
consanguineous	JJ	consanguineous
Turkish	JJ	Turkish
parents	NNS	parent
,	,	,
who	WP	who
was	VBD	be
diagnosed	VBN	diagnose
with	IN	with
the	DT	the
infantile	JJ	infantile
form	NN	form
of	IN	of
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
Two	CD	Two
different	JJ	different
uncommon	JJ	uncommon
homozygote	NN	homozygote
mutations	NNS	mutation
(	(	(
c.32-13	JJ	<unknown>
T	NN	T
>	SYM	>
G	NP	G
homozygote	NN	homozygote
and	CC	and
c.1856G	NNS	<unknown>
>	SYM	>
A	DT	a
homozygote	NN	homozygote
)	)	)
were	VBD	be
detected	VBN	detect
.	SENT	.
The	DT	the
patient	NN	patient
had	VBD	have
a	DT	a
more	RBR	more
progressive	JJ	progressive
clinical	JJ	clinical
course	NN	course
than	IN	than
expected	VBN	expect
.	SENT	.
We	PP	we
emphasize	VBP	emphasize
the	DT	the
rare	JJ	rare
combination	NN	combination
of	IN	of
genetic	JJ	genetic
mutations	NNS	mutation
in	IN	in
this	DT	this
Turkish	JJ	Turkish
family	NN	family
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.⚫	NN	<unknown>
</td>
<td class='article_abstract' colspan='2'>
Late-onset	NN	late-onset
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
(	(	(
LOPD	NP	<unknown>
)	)	)
is	VBZ	be
a	DT	a
metabolic	JJ	metabolic
<span class='symptom'>
myopathy	NN	<unknown>
</span>
caused	VBN	cause
by	IN	by
mutations	NNS	mutation
in	IN	in
<span class='gene'>
GAA	NP	<unknown>
</span>
and	CC	and
characterized	VBN	characterize
by	IN	by
<span class='symptom'>
proximal	JJ	proximal
muscle	NN	muscle
weakness	NN	weakness
</span>
and	CC	and
<span class='symptom'>
respiratory	JJ	respiratory
insufficiency	NN	insufficiency
</span>
.	SENT	.
There	EX	there
is	VBZ	be
evidence	NN	evidence
from	IN	from
clinical	JJ	clinical
studies	NNS	study
that	IN	that
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
with	IN	with
human	JJ	human
recombinant	JJ	recombinant
alpha-glucosidase	NN	<unknown>
improves	VBZ	improve
motor	NN	motor
performance	NN	performance
and	CC	and
respiratory	JJ	respiratory
function	NN	function
in	IN	in
LOPD.We	NP	<unknown>
analyzed	VBD	analyze
quantitative	JJ	quantitative
muscle	NN	muscle
MRI	NP	MRI
data	NNS	datum
of	IN	of
lower	JJR	low
limbs	NNS	limb
to	TO	to
evaluate	VB	evaluate
the	DT	the
effects	NNS	effect
of	IN	of
long-term	JJ	long-term
ERT	NN	ERT
on	IN	on
muscle	NN	muscle
parameters.Three	NN	<unknown>
symptomatic	JJ	symptomatic
LOPD	NP	<unknown>
patients	NNS	patient
who	WP	who
received	VBD	receive
ERT	NN	ERT
for	IN	for
five	CD	five
years	NNS	year
and	CC	and
four	CD	four
untreated	JJ	untreated
presymptomatic	JJ	<unknown>
LOPD	NN	<unknown>
patients	NNS	patient
were	VBD	be
included	VBN	include
in	IN	in
the	DT	the
study	NN	study
.	SENT	.
T1-weighted	NP	<unknown>
MRI	NP	MRI
images	NNS	image
were	VBD	be
used	VBN	use
to	TO	to
determine	VB	determine
volumes	NNS	volume
of	IN	of
thigh	NN	thigh
and	CC	and
lower	JJR	low
leg	NN	leg
muscles	NNS	muscle
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
mean	VBP	mean
gray	JJ	gray
values	NNS	value
of	IN	of
eight	CD	eight
individual	JJ	individual
thigh	NN	thigh
muscles	NNS	muscle
were	VBD	be
calculated	VBN	calculate
to	TO	to
assess	VB	assess
the	DT	the
degree	NN	degree
of	IN	of
lipomatous	JJ	lipomatous
muscle	NN	muscle
alterations.We	NP	<unknown>
detected	VBD	detect
a	DT	a
decrease	NN	decrease
in	IN	in
thigh	NN	thigh
muscle	NN	muscle
volume	NN	volume
of	IN	of
6.7	CD	@card@
%	NN	%
(	(	(
p	NN	p
<	SYM	<
0.001	CD	@card@
)	)	)
and	CC	and
an	DT	an
increase	NN	increase
in	IN	in
lower	JJR	low
leg	NN	leg
muscle	NN	muscle
volume	NN	volume
of	IN	of
8.2	CD	@card@
%	NN	%
(	(	(
p	NN	p
=	SYM	=
0.049	CD	@card@
)	)	)
after	IN	after
five	CD	five
years	NNS	year
of	IN	of
ERT	NN	ERT
.	SENT	.
Analysis	NN	analysis
of	IN	of
individual	JJ	individual
thigh	NN	thigh
muscles	NNS	muscle
revealed	VBD	reveal
a	DT	a
positive	JJ	positive
correlation	NN	correlation
between	IN	between
the	DT	the
degree	NN	degree
of	IN	of
lipomatous	JJ	lipomatous
muscle	NN	muscle
alterations	NNS	alteration
at	IN	at
baseline	NN	baseline
and	CC	and
the	DT	the
increase	NN	increase
of	IN	of
gray	JJ	gray
values	NNS	value
after	IN	after
five	CD	five
years	NNS	year
of	IN	of
ERT	NN	ERT
(	(	(
R(2)	NP	<unknown>
=	SYM	=
0.68	CD	@card@
,	,	,
p	NN	p
<	SYM	<
0.001)	JJ	<unknown>
.	SENT	.
Muscle	NN	muscle
imaging	NN	imaging
in	IN	in
presymptomatic	JJ	<unknown>
patients	NNS	patient
showed	VBD	show
in	IN	in
one	CD	one
case	NN	case
pronounced	VBD	pronounce
lipomatous	JJ	lipomatous
alteration	NN	alteration
of	IN	of
the	DT	the
adductor	NN	adductor
magnus	NN	<unknown>
muscle	NN	muscle
and	CC	and
mild	JJ	mild
to	TO	to
moderate	JJ	moderate
changes	NNS	change
in	IN	in
further	JJR	further
thigh	NN	thigh
muscles.The	NN	<unknown>
results	NNS	result
demonstrate	VBP	demonstrate
that	IN	that
fatty	JJ	fatty
muscle	NN	muscle
degeneration	NN	degeneration
can	MD	can
occur	VB	occur
before	IN	before
clinical	JJ	clinical
manifestation	NN	manifestation
of	IN	of
<span class='symptom'>
muscle	NN	muscle
weakness	NN	weakness
</span>
and	CC	and
suggest	VBP	suggest
that	IN	that
mildly	RB	mildly
affected	VBN	affect
muscles	NNS	muscle
may	MD	may
respond	VB	respond
better	RBR	well
to	TO	to
ERT	NN	ERT
treatment	NN	treatment
than	IN	than
severely	RB	severely
involved	VBN	involve
muscles	NNS	muscle
.	SENT	.
If	IN	if
these	DT	these
findings	NNS	finding
can	MD	can
be	VB	be
validated	VBN	validate
by	IN	by
further	JJR	further
studies	NNS	study
,	,	,
it	PP	it
should	MD	should
be	VB	be
discussed	VBN	discuss
if	IN	if
muscle	NN	muscle
alterations	NNS	alteration
detected	VBN	detect
by	IN	by
muscle	NN	muscle
MRI	NP	MRI
may	MD	may
be	VB	be
an	DT	an
objective	JJ	objective
sign	NN	sign
of	IN	of
disease	NN	disease
manifestation	NN	manifestation
justifying	VBG	justify
an	DT	an
early	JJ	early
start	NN	start
of	IN	of
ERT	NN	ERT
in	IN	in
clinically	RB	clinically
asymptomatic	JJ	asymptomatic
patients	NNS	patient
in	IN	in
order	NN	order
to	TO	to
improve	VB	improve
the	DT	the
long-term	JJ	long-term
outcome.⚫	NN	<unknown>
</td>
<td class='article_abstract' colspan='2'>
Respiratory	NN	<unknown>
and/or	CC	and/or
lingual	JJ	lingual
dysfunction	NN	dysfunction
are	VBP	be
among	IN	among
the	DT	the
first	JJ	first
motor	NN	motor
symptoms	NNS	symptom
in	IN	in
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
a	DT	a
disorder	NN	disorder
resulting	VBG	result
from	IN	from
absence	NN	absence
or	CC	or
dysfunction	NN	dysfunction
of	IN	of
the	DT	the
lysosomal	JJ	lysosomal
enzyme	NN	enzyme
acid	NN	acid
α-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
histologically	RB	histologically
evaluated	VBD	evaluate
the	DT	the
medulla	NN	medulla
,	,	,
cervical	JJ	cervical
and	CC	and
thoracic	JJ	thoracic
spinal	JJ	spinal
cords	NNS	cord
in	IN	in
6	CD	6
weeks	NNS	week
old	JJ	old
asymptomatic	JJ	asymptomatic
Pompe	NP	<unknown>
(Gaa(-/-))	NN	<unknown>
mice	NNS	mouse
to	TO	to
determine	VB	determine
if	IN	if
neuropathology	NN	neuropathology
in	IN	in
respiratory	JJ	respiratory
motor	NN	motor
regions	NNS	region
has	VBZ	have
an	DT	an
early	JJ	early
onset	NN	onset
.	SENT	.
Periodic	JJ	periodic
acid-Schiff	NN	<unknown>
(	(	(
PAS	NP	Pas
)	)	)
staining	VBG	stain
indicated	JJ	indicated
glycogen	NN	glycogen
accumulation	NN	accumulation
was	VBD	be
exclusively	RB	exclusively
occurring	VBG	occur
in	IN	in
Gaa(-/-)	NP	<unknown>
hypoglossal	NN	hypoglossal
,	,	,
mid-cervical	JJ	<unknown>
and	CC	and
upper	JJ	upper
thoracic	JJ	thoracic
motoneurons	NNS	motoneuron
.	SENT	.
Markers	NNS	marker
of	IN	of
DNA	NN	DNA
damage	NN	damage
(	(	(
Tunel	NP	<unknown>
)	)	)
and	CC	and
ongoing	JJ	ongoing
apoptosis	NN	<unknown>
(	(	(
Cleaved	NP	<unknown>
Caspase	NP	<unknown>
3	CD	3
)	)	)
did	VBD	do
not	RB	not
co-localize	VB	<unknown>
with	IN	with
PAS	NP	Pas
staining	VBG	stain
,	,	,
but	CC	but
were	VBD	be
prominent	JJ	prominent
in	IN	in
a	DT	a
medullary	JJ	medullary
region	NN	region
which	WDT	which
included	VBD	include
the	DT	the
nucleus	NN	nucleus
tractus	NN	<unknown>
solitarius	NN	<unknown>
,	,	,
and	CC	and
also	RB	also
in	IN	in
the	DT	the
thoracic	JJ	thoracic
spinal	JJ	spinal
dorsal	JJ	dorsal
horn	NN	horn
.	SENT	.
We	PP	we
conclude	VBP	conclude
that	IN	that
respiratory-related	JJ	<unknown>
motoneurons	NNS	motoneuron
are	VBP	be
particularly	RB	particularly
susceptible	JJ	susceptible
to	TO	to
<span class='gene'>
GAA	NP	<unknown>
</span>
deficiency	NN	deficiency
and	CC	and
that	DT	that
neuronal	JJ	<unknown>
glycogen	NN	glycogen
accumulation	NN	accumulation
and	CC	and
<span class='symptom'>
neurodegeneration	NN	<unknown>
</span>
may	MD	may
occur	VB	occur
independently	RB	independently
in	IN	in
early	JJ	early
stage	NN	stage
disease	NN	disease
.	SENT	.
The	DT	the
data	NNS	datum
support	VBP	support
early	JJ	early
therapeutic	JJ	therapeutic
intervention	NN	intervention
in	IN	in
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
</td>
<td class='article_abstract' colspan='2'>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
(	(	(
PD	NP	PD
)	)	)
is	VBZ	be
a	DT	a
rare	JJ	rare
,	,	,
inherited	JJ	inherited
autosomal	JJ	autosomal
recessive	JJ	recessive
metabolic	JJ	metabolic
disorder	NN	disorder
caused	VBN	cause
by	IN	by
the	DT	the
deficiency	NN	deficiency
of	IN	of
the	DT	the
lysosomal	JJ	lysosomal
acid	NN	acid
alpha-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
enzyme	NN	enzyme
described	VBN	describe
in	IN	in
1932	CD	@card@
by	IN	by
the	DT	the
Dutch	JJ	Dutch
pathologist	NN	pathologist
Joannes	NP	Joannes
Cassianus	NP	<unknown>
Pompe	NP	<unknown>
.	SENT	.
The	DT	the
prevalence	NN	prevalence
of	IN	of
PD	JJ	PD
ranges	NNS	range
from	IN	from
1:40,000	CD	@card@
to	TO	to
1:300,000	CD	@card@
births	NNS	birth
and	CC	and
depends	VBZ	depend
on	IN	on
geographic	JJ	geographic
and	CC	and
ethnic	JJ	ethnic
factors	NNS	factor
.	SENT	.
Clinical	JJ	clinical
manifestations	NNS	manifestation
may	MD	may
vary	VB	vary
from	IN	from
a	DT	a
rapidly	RB	rapidly
progressive	JJ	progressive
disabling	VBG	disable
disease	NN	disease
with	IN	with
<span class='symptom'>
cardiomegaly	NN	cardiomegaly
</span>
,	,	,
<span class='symptom'>
hepatomegaly	RB	<unknown>
</span>
,	,	,
<span class='symptom'>
weakness	NN	weakness
</span>
,	,	,
<span class='symptom'>
generalized	VBN	generalize
hypotonia	NN	<unknown>
</span>
,	,	,
and	CC	and
death	NN	death
within	IN	within
the	DT	the
first	JJ	first
year	NN	year
of	IN	of
life	NN	life
,	,	,
to	TO	to
a	DT	a
mild	JJ	mild
presentation	NN	presentation
characterized	VBN	characterize
by	IN	by
slowly	RB	slowly
progressive	JJ	progressive
<span class='symptom'>
myopathy	NN	<unknown>
</span>
predominantly	RB	predominantly
involving	VBG	involve
the	DT	the
skeletal	JJ	skeletal
muscles	NNS	muscle
.	SENT	.
The	DT	the
laboratory	NN	laboratory
diagnostic	JJ	diagnostic
gold	NN	gold
standard	NN	standard
is	VBZ	be
represented	VBN	represent
by	IN	by
the	DT	the
determination	NN	determination
of	IN	of
the	DT	the
alpha-glucosidase	NN	<unknown>
activity	NN	activity
.	SENT	.
However	RB	however
,	,	,
the	DT	the
muscle	NN	muscle
histology	NN	histology
may	MD	may
also	RB	also
yield	VB	yield
the	DT	the
diagnosis	NN	diagnosis
by	IN	by
evaluating	VBG	evaluate
the	DT	the
tissular	JJ	<unknown>
glycogen	NN	glycogen
accumulation	NN	accumulation
.	SENT	.
Until	IN	until
recently	RB	recently
,	,	,
supportive	JJ	supportive
measures	NNS	measure
constituted	VBD	constitute
the	DT	the
unique	JJ	unique
available	JJ	available
therapy	NN	therapy
.	SENT	.
Currently	RB	currently
,	,	,
the	DT	the
administration	NN	administration
of	IN	of
the	DT	the
recombinant	JJ	recombinant
<span class='gene'>
GAA	NP	<unknown>
</span>
is	VBZ	be
being	VBG	be
used	VBN	use
with	IN	with
promising	JJ	promising
results	NNS	result
.	SENT	.
The	DT	the
authors	NNS	author
present	VBP	present
the	DT	the
case	NN	case
of	IN	of
a	DT	a
5-month-old	JJ	<unknown>
boy	NN	boy
,	,	,
previously	RB	previously
diagnosed	VBN	diagnose
with	IN	with
<span class='symptom'>
hypertrophic	JJ	hypertrophic
cardiomyopathy	NN	<unknown>
</span>
since	IN	since
the	DT	the
age	NN	age
of	IN	of
2	CD	2
months	NNS	month
,	,	,
who	WP	who
presented	VBD	present
acute	JJ	acute
<span class='symptom'>
heart	NN	heart
failure	NN	failure
</span>
accompanied	VBN	accompany
by	IN	by
biventricular	JJ	<unknown>
dilation	NN	dilation
followed	VBN	follow
by	IN	by
refractory	JJ	refractory
shock	NN	shock
and	CC	and
death	NN	death
.	SENT	.
The	DT	the
autopsy	NN	autopsy
findings	NNS	finding
confirmed	VBD	confirm
the	DT	the
glycogen-accumulation	NN	<unknown>
disease.⚫	JJ	<unknown>
</td>
<td class='article_abstract' colspan='2'>
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
is	VBZ	be
an	DT	an
inherited	JJ	inherited
disorder	NN	disorder
notable	JJ	notable
for	IN	for
severe	JJ	severe
,	,	,
progressive	JJ	progressive
ventilatory	JJ	ventilatory
compromise	NN	compromise
.	SENT	.
Although	IN	although
ventilatory	JJ	ventilatory
failure	NN	failure
has	VBZ	have
been	VBN	be
attributed	VBN	attribute
to	TO	to
myofiber	NN	<unknown>
dysfunction	NN	dysfunction
secondary	JJ	secondary
to	TO	to
diaphragmatic	JJ	diaphragmatic
glycogen	NN	glycogen
accumulation	NN	accumulation
,	,	,
neural	JJ	neural
involvement	NN	involvement
of	IN	of
the	DT	the
phrenic	JJ	phrenic
motor	NN	motor
system	NN	system
is	VBZ	be
also	RB	also
a	DT	a
prominent	JJ	prominent
feature	NN	feature
.	SENT	.
Direct	JJ	direct
diaphragm	NN	diaphragm
pacing	VBG	pace
supplements	NNS	supplement
respiratory	JJ	respiratory
function	NN	function
in	IN	in
other	JJ	other
disorders	NNS	disorder
of	IN	of
the	DT	the
phrenic	JJ	phrenic
motor	NN	motor
system	NN	system
.	SENT	.
Accordingly	RB	accordingly
,	,	,
it	PP	it
is	VBZ	be
hypothesized	VBN	hypothesize
that	IN	that
augmented	JJ	augmented
neuromuscular	JJ	neuromuscular
activity	NN	activity
via	IN	via
diaphragm	NN	diaphragm
pacing	VBG	pace
would	MD	would
promote	VB	promote
weaning	VBG	wean
from	IN	from
mechanical	JJ	mechanical
ventilation	NN	ventilation
in	IN	in
patients	NNS	patient
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
who	WP	who
are	VBP	be
unresponsive	JJ	unresponsive
to	TO	to
conventional	JJ	conventional
,	,	,
muscle-directed	JJ	<unknown>
treatments.Three	NN	<unknown>
patients	NNS	patient
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
developed	VBD	develop
diaphragm	NN	diaphragm
paresis	NN	paresis
that	WDT	that
resulted	VBD	result
in	IN	in
chronic	JJ	chronic
mechanical	JJ	mechanical
ventilation	NN	ventilation
dependence	NN	dependence
.	SENT	.
After	IN	after
preoperative	JJ	<unknown>
inspiratory	JJ	inspiratory
muscle	NN	muscle
strengthening	NN	strengthening
exercises	NNS	exercise
failed	VBD	fail
to	TO	to
improve	VB	improve
function	NN	function
,	,	,
fine-wire	NN	<unknown>
pacing	VBG	pace
electrodes	NNS	electrode
were	VBD	be
laparoscopically	RB	<unknown>
implanted	VBN	implant
into	IN	into
the	DT	the
diaphragm	NN	diaphragm
.	SENT	.
Diaphragm	NN	diaphragm
conditioning	NN	conditioning
was	VBD	be
initiated	VBN	initiate
the	DT	the
first	JJ	first
postoperative	JJ	postoperative
week	NN	week
and	CC	and
consisted	VBN	consist
of	IN	of
gradual	JJ	gradual
increases	NNS	increase
in	IN	in
stimulation	NN	stimulation
parameters	NNS	parameter
,	,	,
lengthening	VBG	lengthen
of	IN	of
stimulation	NN	stimulation
sessions	NNS	session
,	,	,
and	CC	and
ventilator	NN	ventilator
weaning	VBG	wean
.	SENT	.
Ventilation	NN	ventilation
and	CC	and
intramuscular	JJ	intramuscular
electromyographic	JJ	<unknown>
activity	NN	activity
were	VBD	be
recorded	VBN	record
periodically	RB	periodically
during	IN	during
conditioning	NN	conditioning
to	TO	to
quantify	VB	quantify
diaphragm	NN	diaphragm
neuromuscular	JJ	neuromuscular
function.During	NN	<unknown>
paced	VBD	pace
breathing	VBG	breathe
without	IN	without
mechanical	JJ	mechanical
ventilation	NN	ventilation
,	,	,
tidal	JJ	tidal
volumes	NNS	volume
increased	VBD	increase
,	,	,
and	CC	and
2	CD	2
patients	NNS	patient
were	VBD	be
weaned	VBN	wean
from	IN	from
daytime	JJ	daytime
ventilator	NN	ventilator
dependence	NN	dependence
within	IN	within
the	DT	the
first	JJ	first
3	CD	3
months	NNS	month
of	IN	of
pacing	VBG	pace
,	,	,
which	WDT	which
has	VBZ	have
been	VBN	be
sustained	VBN	sustain
over	IN	over
the	DT	the
long-term	JJ	long-term
.	SENT	.
A	DT	a
third	JJ	third
patient	NN	patient
reduced	VBD	reduce
reliance	NN	reliance
on	IN	on
daytime	JJ	daytime
ventilation	NN	ventilation
,	,	,
but	CC	but
weaning	VBG	wean
was	VBD	be
delayed	VBN	delay
by	IN	by
malacia	NNS	<unknown>
of	IN	of
the	DT	the
large	JJ	large
airways	NNS	airway
.	SENT	.
In	IN	in
all	DT	all
patients	NNS	patient
,	,	,
pacing	VBG	pace
appeared	VBD	appear
to	TO	to
facilitate	VB	facilitate
spontaneous	JJ	spontaneous
phrenic	JJ	phrenic
motor	NN	motor
unit	NN	unit
activity	NN	activity
during	IN	during
independent	JJ	independent
breathing	NN	breathing
without	IN	without
ventilator	NN	ventilator
or	CC	or
pacer	NN	pacer
support.The	NN	<unknown>
findings	NNS	finding
are	VBP	be
consistent	JJ	consistent
with	IN	with
the	DT	the
view	NN	view
that	IN	that
diaphragm	NN	diaphragm
pacing	VBG	pace
has	VBZ	have
potential	JJ	potential
rehabilitative	JJ	rehabilitative
value	NN	value
to	TO	to
reduce	VB	reduce
reliance	NN	reliance
on	IN	on
mechanical	JJ	mechanical
ventilation	NN	ventilation
in	IN	in
people	NNS	people
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
but	CC	but
further	JJR	further
study	NN	study
is	VBZ	be
needed	VBN	need
.	SENT	.
Diaphragm	NN	diaphragm
pacing	VBG	pace
represents	VBZ	represent
a	DT	a
paradigm	NN	paradigm
shift	NN	shift
in	IN	in
the	DT	the
management	NN	management
of	IN	of
<span class='symptom'>
respiratory	JJ	respiratory
insufficiency	NN	insufficiency
</span>
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
that	WDT	that
warrants	VBZ	warrant
further	RBR	further
controlled	VBN	control
examination.⚫	JJ	<unknown>
</td>
<td class='article_abstract' colspan='2'>
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
also	RB	also
known	VBN	know
as	IN	as
glycogen	NN	glycogen
storage	NN	storage
disease	NN	disease
type	NN	type
II	NP	II
,	,	,
is	VBZ	be
caused	VBN	cause
by	IN	by
acid	JJ	acid
maltase	NN	maltase
deficiency	NN	deficiency
,	,	,
and	CC	and
can	MD	can
lead	VB	lead
to	TO	to
lysosomal	JJ	lysosomal
glycogen	NN	glycogen
storage	NN	storage
.	SENT	.
The	DT	the
primal	JJ	primal
manifestations	NNS	manifestation
may	MD	may
be	VB	be
observed	VBN	observe
in	IN	in
children	NNS	child
and	CC	and
adults	NNS	adult
,	,	,
and	CC	and
also	RB	also
in	IN	in
infants	NNS	infant
.	SENT	.
In	IN	in
general	NN	general
,	,	,
the	DT	the
clinical	JJ	clinical
spectrum	NN	spectrum
in	IN	in
infants	NNS	infant
is	VBZ	be
more	RBR	more
progressive	JJ	progressive
and	CC	and
lethal	JJ	lethal
than	IN	than
that	IN	that
in	IN	in
older	JJR	old
patients	NNS	patient
.	SENT	.
This	DT	this
case	NN	case
report	NN	report
describes	VBZ	describe
the	DT	the
case	NN	case
of	IN	of
a	DT	a
newborn	NN	newborn
who	WP	who
was	VBD	be
found	VBN	find
to	TO	to
have	VB	have
cardiac	JJ	cardiac
hypertrophy	NN	hypertrophy
,	,	,
<span class='symptom'>
hepatomegaly	JJ	<unknown>
</span>
and	CC	and
elevated	JJ	elevated
serum	NN	serum
enzyme	NN	enzyme
levels	NNS	level
,	,	,
which	WDT	which
was	VBD	be
characterized	VBN	characterize
by	IN	by
an	DT	an
aspartate	JJ	<unknown>
aminotransferase	NN	<unknown>
level	NN	level
of	IN	of
95	CD	@card@
U/l	NN	<unknown>
,	,	,
lactate	NN	lactate
dehydrogenase	NN	dehydrogenase
level	NN	level
of	IN	of
778	CD	@card@
U/l	NN	<unknown>
and	CC	and
creatine	NN	creatine
kinase	NN	kinase
level	NN	level
of	IN	of
1,299	CD	@card@
U/l	NN	<unknown>
.	SENT	.
On	IN	on
the	DT	the
basis	NN	basis
of	IN	of
the	DT	the
clinical	JJ	clinical
signs	NNS	sign
and	CC	and
laboratory	NN	laboratory
results	NNS	result
,	,	,
dried	VBD	dry
blood	NN	blood
spots	NNS	spot
from	IN	from
the	DT	the
baby	NN	baby
were	VBD	be
tested	VBN	test
to	TO	to
determine	VB	determine
the	DT	the
acid	JJ	acid
α-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
activity	NN	activity
,	,	,
and	CC	and
the	DT	the
result	NN	result
confirmed	VBD	confirm
that	IN	that
the	DT	the
<span class='gene'>
GAA	NP	<unknown>
</span>
activity	NN	activity
was	VBD	be
only	RB	only
0.10	CD	@card@
pmol/punch/h	NN	<unknown>
(	(	(
normal	JJ	normal
reference	NN	reference
range	NN	range
,	,	,
2.88-89.02	CD	@card@
pmol/punch/h	NN	<unknown>
)	)	)
at	IN	at
pH	NN	pH
3.8	CD	@card@
,	,	,
which	WDT	which
was	VBD	be
clearly	RB	clearly
lower	JJR	low
than	IN	than
the	DT	the
normal	JJ	normal
range	NN	range
,	,	,
leading	VBG	lead
to	TO	to
a	DT	a
diagnosis	NN	diagnosis
of	IN	of
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
incurable	JJ	incurable
,	,	,
and	CC	and
before	IN	before
the	DT	the
introduction	NN	introduction
of	IN	of
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
,	,	,
pain	NN	pain
relief	NN	relief
was	VBD	be
the	DT	the
main	JJ	main
treatment	NN	treatment
.	SENT	.
Recognizing	VBG	recognize
this	DT	this
disease	NN	disease
earlier	RBR	earlier
and	CC	and
starting	VBG	start
ERT	NN	ERT
in	IN	in
infants	NNS	infant
prior	RB	prior
to	TO	to
the	DT	the
development	NN	development
of	IN	of
clinical	JJ	clinical
symptoms	NNS	symptom
is	VBZ	be
likely	JJ	likely
to	TO	to
improve	VB	improve
the	DT	the
quality	NN	quality
of	IN	of
life	NN	life
of	IN	of
patients	NNS	patient
.	SENT	.
</td>
<td class='article_abstract' colspan='2'>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
an	DT	an
autosomal	JJ	autosomal
recessive	JJ	recessive
disease	NN	disease
resulting	VBG	result
from	IN	from
deficiency	NN	deficiency
of	IN	of
the	DT	the
acid	JJ	acid
alpha-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
.	SENT	.
The	DT	the
late-onset	NN	late-onset
<span class='disease'>
Pompe	NP	<unknown>
Disease	NP	Disease
</span>
(	(	(
LOPD	NP	<unknown>
)	)	)
patients	NNS	patient
develop	VBP	develop
muscular	JJ	muscular
and	CC	and
respiratory	JJ	respiratory
complications	NNS	complication
later	RBR	later
in	IN	in
life	NN	life
.	SENT	.
We	PP	we
describe	VBP	describe
a	DT	a
retrospective	JJ	retrospective
observational	JJ	observational
cohort	NN	cohort
study	NN	study
including	VBG	include
22	CD	@card@
patients	NNS	patient
with	IN	with
LOPD	NP	<unknown>
.	SENT	.
The	DT	the
cohort	NN	cohort
was	VBD	be
assessed	VBN	assess
at	IN	at
baseline	NN	baseline
before	IN	before
Enzyme	NP	<unknown>
Replacement	NP	<unknown>
Therapy	NP	<unknown>
(	(	(
ERT	NN	ERT
)	)	)
with	IN	with
alglucosidase	NN	<unknown>
alpha	NN	alpha
(	(	(
20mg/kg	JJ	<unknown>
biweekly	NN	biweekly
)	)	)
was	VBD	be
commenced	VBN	commence
and	CC	and
subsequently	RB	subsequently
relevant	JJ	relevant
information	NN	information
was	VBD	be
collected	VBN	collect
at	IN	at
2	CD	2
,	,	,
4	CD	4
and	CC	and
5years	NNS	<unknown>
later	RBR	later
.	SENT	.
The	DT	the
median	JJ	median
age	NN	age
of	IN	of
the	DT	the
patients	NNS	patient
at	IN	at
study	NN	study
entry	NN	entry
was	VBD	be
44years	JJ	<unknown>
(	(	(
16-64years	NNS	<unknown>
)	)	)
,	,	,
with	IN	with
median	JJ	median
disease	NN	disease
duration	NN	duration
of	IN	of
11.5years	JJ	<unknown>
(4-31years)	NN	<unknown>
.	SENT	.
At	IN	at
baseline	NN	baseline
,	,	,
10	CD	@card@
patients	NNS	patient
(	(	(
45	CD	@card@
%	NN	%
)	)	)
could	MD	could
walk	VB	walk
without	IN	without
support	NN	support
,	,	,
12	CD	@card@
(	(	(
55	CD	@card@
%	NN	%
)	)	)
could	MD	could
walk	VB	walk
with	IN	with
unilateral	JJ	unilateral
or	CC	or
bilateral	JJ	bilateral
support	NN	support
including	VBG	include
3/12	CD	@card@
were	VBD	be
wheelchair	NN	wheelchair
bound	VBN	bind
.	SENT	.
Mean	NN	mean
predicted	VBD	predict
FVC	NP	<unknown>
%	NN	%
was	VBD	be
55.7	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
45-66	CD	@card@
)	)	)
of	IN	of
predicted	VBN	predict
normal	JJ	normal
at	IN	at
baseline	NN	baseline
and	CC	and
showed	VBD	show
no	DT	no
significant	JJ	significant
change	NN	change
after	IN	after
5years	NNS	<unknown>
(	(	(
54.6	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
43-66	CD	@card@
)	)	)
)	)	)
,	,	,
(	(	(
all	DT	all
p=0.9815)	NN	<unknown>
.	SENT	.
Mean	JJ	mean
FVC	NP	<unknown>
%	NN	%
supine	NN	supine
was	VBD	be
41.8	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
33.8-49	CD	@card@
)	)	)
of	IN	of
predicted	VBN	predict
normal	JJ	normal
at	IN	at
baseline	NN	baseline
and	CC	and
remained	VBD	remain
significantly	RB	significantly
unchanged	JJ	unchanged
at	IN	at
5years	NNS	<unknown>
(	(	(
48.4	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
37-59.6	CD	@card@
)	)	)
)	)	)
,	,	,
(	(	(
all	DT	all
p=0.8680)	NN	<unknown>
.	SENT	.
The	DT	the
overnight	JJ	overnight
non-invasive	JJ	non-invasive
ventilator	NN	ventilator
dependence	NN	dependence
increased	VBN	increase
by	IN	by
18.2	CD	@card@
%	NN	%
as	IN	as
compared	VBN	compare
with	IN	with
baseline	NN	baseline
and	CC	and
requirement	NN	requirement
of	IN	of
mobility	NN	mobility
aids	NNS	aid
increased	VBN	increase
during	IN	during
this	DT	this
period	NN	period
by	IN	by
5.2	CD	@card@
%	NN	%
as	IN	as
compared	VBN	compare
with	IN	with
the	DT	the
baseline	NN	baseline
.	SENT	.
Mean	VB	mean
walking	VBG	walk
distance	NN	distance
at	IN	at
6min	JJ	<unknown>
walk	NN	walk
test	NN	test
was	VBD	be
411.5	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
338-485	CD	@card@
)	)	)
at	IN	at
baseline	NN	baseline
,	,	,
266.5	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
187-346	CD	@card@
)	)	)
m	NN	m
at	IN	at
2years	NNS	<unknown>
,	,	,
238.6	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
162-315	CD	@card@
)	)	)
m	NN	m
at	IN	at
4years	NNS	<unknown>
and	CC	and
286.8	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
203-370	CD	@card@
)	)	)
m	NN	m
at	IN	at
5years	NNS	<unknown>
(	(	(
p=0.1981	NP	<unknown>
;	:	;
ANOVA	NP	<unknown>
was	VBD	be
completed	VBN	complete
only	RB	only
for	IN	for
14	CD	@card@
patients)	NN	<unknown>
.	SENT	.
A	DT	a
gradual	JJ	gradual
decline	NN	decline
in	IN	in
FVC	NP	<unknown>
%	NN	%
predicted	VBD	predict
was	VBD	be
noted	VBN	note
only	RB	only
in	IN	in
four	CD	four
cases	NNS	case
and	CC	and
a	DT	a
decline	NN	decline
in	IN	in
FVC	NP	<unknown>
%	NN	%
supine	NN	supine
in	IN	in
two	CD	two
other	JJ	other
.	SENT	.
Only	RB	only
one	CD	one
patient	NN	patient
showed	VBD	show
a	DT	a
decline	NN	decline
in	IN	in
both	DT	both
pulmonary	JJ	pulmonary
function	NN	function
tests	NNS	test
.	SENT	.
In	IN	in
all	DT	all
remaining	VBG	remain
cases	NNS	case
(	(	(
17/22	CD	@card@
)	)	)
respiratory	JJ	respiratory
function	NN	function
remains	VBZ	remain
stable	JJ	stable
.	SENT	.
In	IN	in
conclusion	NN	conclusion
overall	JJ	overall
pulmonary	JJ	pulmonary
function	NN	function
tests	NNS	test
and	CC	and
mobility	NN	mobility
remained	VBD	remain
stable	JJ	stable
for	IN	for
5years	NNS	<unknown>
in	IN	in
majority	NN	majority
of	IN	of
patients	NNS	patient
on	IN	on
ERT	NN	ERT
.	SENT	.
However	RB	however
,	,	,
in	IN	in
some	DT	some
patients	NNS	patient
they	PP	they
continued	VBD	continue
to	TO	to
decline	VB	decline
in	IN	in
spite	NN	spite
of	IN	of
ERT	NN	ERT
resulting	VBG	result
in	IN	in
increased	VBN	increase
number	NN	number
of	IN	of
patients	NNS	patient
requiring	VBG	require
ventilation	NN	ventilation
and	CC	and
increase	NN	increase
wheel	NN	wheel
chair	NN	chair
dependence	NN	dependence
at	IN	at
the	DT	the
end	NN	end
of	IN	of
5years.⚫	NP	<unknown>
</td>
<td class='article_abstract' colspan='2'>
Pompe	NP	<unknown>
or	CC	or
Glycogen	NP	<unknown>
Storage	NP	Storage
Disease	NP	Disease
type	NN	type
II	NP	II
(	(	(
GSD-II	NP	<unknown>
)	)	)
is	VBZ	be
a	DT	a
genetic	JJ	genetic
disorder	NN	disorder
affecting	VBG	affect
both	DT	both
cardiac	JJ	cardiac
and	CC	and
skeletal	JJ	skeletal
muscle	NN	muscle
.	SENT	.
Historically	RB	historically
,	,	,
patients	NNS	patient
with	IN	with
the	DT	the
infantile	JJ	infantile
form	NN	form
usually	RB	usually
die	VB	die
within	IN	within
the	DT	the
first	JJ	first
year	NN	year
of	IN	of
life	NN	life
due	JJ	due
to	TO	to
cardiac	JJ	cardiac
and	CC	and
<span class='symptom'>
respiratory	JJ	respiratory
failure	NN	failure
</span>
.	SENT	.
Recently	RB	recently
a	DT	a
promising	JJ	promising
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
has	VBZ	have
resulted	VBN	result
in	IN	in
improved	VBN	improve
clinical	JJ	clinical
outcomes	NNS	outcome
and	CC	and
a	DT	a
resurgence	NN	resurgence
of	IN	of
elective	JJ	elective
anesthesia	NN	anesthesia
for	IN	for
these	DT	these
patients	NNS	patient
.	SENT	.
Understanding	VBG	understand
the	DT	the
unique	JJ	unique
cardiac	JJ	cardiac
physiology	NN	physiology
in	IN	in
patients	NNS	patient
with	IN	with
GSD-II	NP	<unknown>
is	VBZ	be
essential	JJ	essential
to	TO	to
providing	VBG	provide
safe	JJ	safe
general	JJ	general
anesthesia	NN	anesthesia
.	SENT	.
Additional	JJ	additional
care	NN	care
in	IN	in
maximizing	VBG	maximize
coronary	JJ	coronary
perfusion	NN	perfusion
pressure	NN	pressure
and	CC	and
minimizing	VBG	minimize
<span class='symptom'>
arrhythmia	NN	arrhythmia
</span>
risk	NN	risk
must	MD	must
be	VB	be
given	VBN	give
.	SENT	.
For	IN	for
these	DT	these
reasons	NNS	reason
,	,	,
it	PP	it
is	VBZ	be
recommended	VBN	recommend
that	IN	that
anesthesia	NN	anesthesia
for	IN	for
infantile	JJ	infantile
Pompe	NP	<unknown>
patients	NNS	patient
should	MD	should
specifically	RB	specifically
avoid	VB	avoid
propofol	NN	<unknown>
or	CC	or
high	JJ	high
concentrations	NNS	concentration
of	IN	of
sevoflurane	NN	<unknown>
and	CC	and
,	,	,
instead	RB	instead
,	,	,
use	VBP	use
an	DT	an
agent	NN	agent
such	JJ	such
as	IN	as
ketamine	NN	<unknown>
as	IN	as
the	DT	the
cornerstone	NN	cornerstone
for	IN	for
induction	NN	induction
in	IN	in
order	NN	order
to	TO	to
better	RBR	well
support	VB	support
coronary	JJ	coronary
perfusion	NN	perfusion
pressure	NN	pressure
and	CC	and
to	TO	to
avoid	VB	avoid
decreasing	VBG	decrease
diastolic	JJ	diastolic
blood	NN	blood
pressure	NN	pressure
(	(	(
<span class='gene'>
DBP	NP	<unknown>
</span>
)	)	)
with	IN	with
vasodilatory	JJ	<unknown>
agents	NNS	agent
.	SENT	.
We	PP	we
present	VBP	present
the	DT	the
anesthetic	JJ	anesthetic
technique	NN	technique
in	IN	in
a	DT	a
case	NN	case
of	IN	of
infantile	JJ	infantile
type	NN	type
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.⚫	NN	<unknown>
</td>
<td class='article_abstract' colspan='2'>
Enzyme	NN	enzyme
and	CC	and
gene	NN	gene
replacement	NN	replacement
strategies	NNS	strategy
have	VBP	have
developed	VBN	develop
into	IN	into
viable	JJ	viable
therapeutic	JJ	therapeutic
approaches	NNS	approach
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
(	(	(
acid	JJ	acid
α-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
deficiency)	NN	<unknown>
.	SENT	.
Unfortunately	RB	unfortunately
,	,	,
the	DT	the
introduction	NN	introduction
of	IN	of
<span class='gene'>
GAA	NP	<unknown>
</span>
and	CC	and
viral	JJ	viral
vectors	NNS	vector
encoding	VBG	encode
the	DT	the
enzyme	NN	enzyme
can	MD	can
lead	VB	lead
to	TO	to
detrimental	JJ	detrimental
immune	JJ	immune
responses	NNS	response
that	WDT	that
attenuate	VBP	attenuate
treatment	NN	treatment
benefits	NNS	benefit
and	CC	and
can	MD	can
<span class='gene'>
impact	VB	impact
</span>
patient	JJ	patient
safety	NN	safety
.	SENT	.
Preclinical	JJ	preclinical
and	CC	and
clinical	JJ	clinical
experience	NN	experience
in	IN	in
addressing	VBG	address
humoral	JJ	humoral
responses	NNS	response
toward	IN	toward
enzyme	NN	enzyme
and	CC	and
gene	NN	gene
therapy	NN	therapy
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
have	VBP	have
provided	VBN	provide
greater	JJR	great
understanding	NN	understanding
of	IN	of
the	DT	the
immunological	JJ	immunological
consequences	NNS	consequence
of	IN	of
the	DT	the
provided	VBN	provide
therapy	NN	therapy
.	SENT	.
B-	NP	B-
and	CC	and
T-cell	NN	T-cell
modulation	NN	modulation
has	VBZ	have
been	VBN	be
shown	VBN	show
to	TO	to
be	VB	be
effective	JJ	effective
in	IN	in
preventing	VBG	prevent
infusion-associated	JJ	<unknown>
reactions	NNS	reaction
during	IN	during
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
in	IN	in
patients	NNS	patient
and	CC	and
has	VBZ	have
shown	VBN	show
similar	JJ	similar
success	NN	success
in	IN	in
the	DT	the
context	NN	context
of	IN	of
gene	NN	gene
therapy	NN	therapy
.	SENT	.
Additional	JJ	additional
techniques	NNS	technique
to	TO	to
induce	VB	induce
humoral	JJ	humoral
tolerance	NN	tolerance
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
have	VBP	have
been	VBN	be
the	DT	the
targeted	JJ	targeted
expression	NN	expression
or	CC	or
delivery	NN	delivery
of	IN	of
<span class='gene'>
GAA	NP	<unknown>
</span>
to	TO	to
discrete	JJ	discrete
cell	NN	cell
types	NNS	type
or	CC	or
tissues	NNS	tissue
such	JJ	such
as	IN	as
the	DT	the
gut-associated	JJ	<unknown>
lymphoid	JJ	lymphoid
tissues	NNS	tissue
,	,	,
red	JJ	red
blood	NN	blood
cells	NNS	cell
,	,	,
hematopoietic	JJ	hematopoietic
stem	NN	stem
cells	NNS	cell
,	,	,
and	CC	and
the	DT	the
liver	NN	liver
.	SENT	.
Research	NN	research
into	IN	into
overcoming	VBG	overcome
preexisting	VBG	preexist
immunity	NN	immunity
through	IN	through
immunomodulation	NN	<unknown>
and	CC	and
gene	NN	gene
transfer	NN	transfer
are	VBP	be
becoming	VBG	become
increasingly	RB	increasingly
important	JJ	important
to	TO	to
achieve	VB	achieve
long-term	JJ	long-term
efficacy	NN	efficacy
.	SENT	.
This	DT	this
review	NN	review
highlights	VBZ	highlight
the	DT	the
advances	NNS	advance
in	IN	in
therapies	NNS	therapy
as	RB	as
well	RB	well
as	IN	as
the	DT	the
improved	VBN	improve
understanding	NN	understanding
of	IN	of
the	DT	the
molecular	JJ	molecular
mechanisms	NNS	mechanism
involved	VBN	involve
in	IN	in
the	DT	the
humoral	JJ	humoral
immune	JJ	immune
response	NN	response
with	IN	with
emphasis	NN	emphasis
on	IN	on
methods	NNS	method
employed	VBN	employ
to	TO	to
overcome	VB	overcome
responses	NNS	response
associated	VBN	associate
with	IN	with
enzyme	NN	enzyme
and	CC	and
gene	NN	gene
therapies	NNS	therapy
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.⚫	NN	<unknown>
</td>
<td class='article_abstract' colspan='2'>
Infantile	NP	<unknown>
Onset	NP	<unknown>
<span class='disease'>
Pompe	NP	<unknown>
Disease	NP	Disease
</span>
(	(	(
IOPD	NP	<unknown>
)	)	)
is	VBZ	be
a	DT	a
rare	JJ	rare
autosomal	JJ	autosomal
recessive	JJ	recessive
neuromuscular	JJ	neuromuscular
disorder	NN	disorder
.	SENT	.
It	PP	it
is	VBZ	be
associated	VBN	associate
with	IN	with
<span class='symptom'>
cardiomegaly	NN	cardiomegaly
</span>
,	,	,
hypotonia	NN	<unknown>
,	,	,
paresis	NN	paresis
,	,	,
and	CC	and
death	NN	death
in	IN	in
the	DT	the
first	JJ	first
year	NN	year
of	IN	of
life	NN	life
.	SENT	.
Since	IN	since
2006	CD	@card@
,	,	,
following	VBG	follow
the	DT	the
use	NN	use
of	IN	of
Alglucosidase	NN	<unknown>
alfa	NN	<unknown>
as	IN	as
Enzyme	NP	<unknown>
Replacement	NP	<unknown>
Therapy	NP	<unknown>
(	(	(
ERT	NN	ERT
)	)	)
,	,	,
the	DT	the
patients	NNS	patient
'	POS	'
survival	NN	survival
is	VBZ	be
improved	VBN	improve
to	TO	to
a	DT	a
noticeable	JJ	noticeable
extent.The	NN	<unknown>
purpose	NN	purpose
of	IN	of
this	DT	this
study	NN	study
is	VBZ	be
to	TO	to
examine	VB	examine
the	DT	the
outcome	NN	outcome
of	IN	of
IOPD	JJ	<unknown>
patients	NNS	patient
in	IN	in
South	NP	South
of	IN	of
Iran	NP	Iran
and	CC	and
the	DT	the
degree	NN	degree
of	IN	of
responsiveness	NN	responsiveness
to	TO	to
ERT.All	NP	<unknown>
patients	NNS	patient
who	WP	who
were	VBD	be
diagnosed	VBN	diagnose
with	IN	with
IOPD	NN	<unknown>
on	IN	on
the	DT	the
bases	NNS	base
of	IN	of
clinical	JJ	clinical
symptoms	NNS	symptom
,	,	,
and	CC	and
enzyme	NN	enzyme
assay	NN	assay
on	IN	on
dried	VBN	dry
blood	NN	blood
spot	NN	spot
,	,	,
were	VBD	be
included	VBN	include
in	IN	in
the	DT	the
study	NN	study
;	:	;
and	CC	and
were	VBD	be
followed	VBN	follow
up	RP	up
regarding	VBG	regard
cardiac	JJ	cardiac
function	NN	function
,	,	,
locomotor	JJ	locomotor
activity	NN	activity
,	,	,
and	CC	and
cognition.Six	NN	<unknown>
patients	NNS	patient
with	IN	with
IOPD	NN	<unknown>
were	VBD	be
identified	VBN	identify
.	SENT	.
All	PDT	All
these	DT	these
six	CD	six
patients	NNS	patient
suffered	VBN	suffer
from	IN	from
<span class='symptom'>
Hypertrophic	NP	<unknown>
Cardiomyopathy	NP	<unknown>
</span>
(HCM)	NN	<unknown>
.	SENT	.
Four	NP	Four
(	(	(
67	CD	@card@
%	NN	%
)	)	)
of	IN	of
them	PP	them
also	RB	also
had	VBD	have
<span class='symptom'>
generalized	VBN	generalize
hypotonia	NN	<unknown>
</span>
.	SENT	.
Three	CD	Three
patients	NNS	patient
expired	VBN	expire
during	IN	during
the	DT	the
first	JJ	first
weeks	NNS	week
due	JJ	due
to	TO	to
severe	JJ	severe
<span class='symptom'>
respiratory	JJ	respiratory
infection	NN	infection
</span>
.	SENT	.
One	CD	One
of	IN	of
them	PP	them
also	RB	also
got	VBD	get
involved	VBN	involve
with	IN	with
Acute	JJ	acute
Cardiopulmonary	JJ	cardiopulmonary
Failure	NN	failure
while	IN	while
receiving	VBG	receive
the	DT	the
fifth	JJ	fifth
dose	NN	dose
of	IN	of
ERT	NN	ERT
;	:	;
and	CC	and
expired	VBD	expire
.	SENT	.
However	RB	however
,	,	,
the	DT	the
remaining	VBG	remain
two	CD	two
patients	NNS	patient
had	VBD	have
a	DT	a
significant	JJ	significant
improvement	NN	improvement
after	IN	after
the	DT	the
maximum	NN	maximum
of	IN	of
117	CD	@card@
weeks	NNS	week
of	IN	of
following	VBG	follow
up	RP	up
both	DT	both
cardiac	JJ	cardiac
and	CC	and
locomotor	JJ	locomotor
findings	NNS	finding
.	SENT	.
These	DT	these
two	CD	two
patients	NNS	patient
were	VBD	be
the	DT	the
same	JJ	same
patients	NNS	patient
who	WP	who
showed	VBD	show
cardiac	JJ	cardiac
symptoms	NNS	symptom
from	IN	from
the	DT	the
beginning	NN	beginning
but	CC	but
did	VBD	do
not	RB	not
have	VB	have
<span class='symptom'>
generalized	VBN	generalize
hypotonia	NN	<unknown>
</span>
.Although	NN	<unknown>
ERT	NN	ERT
has	VBZ	have
a	DT	a
significant	JJ	significant
effect	NN	effect
on	IN	on
enhancing	VBG	enhance
the	DT	the
survival	NN	survival
of	IN	of
IOPD	JJ	<unknown>
patients	NNS	patient
,	,	,
it	PP	it
should	MD	should
be	VB	be
associated	VBN	associate
with	IN	with
meticulous	JJ	meticulous
heart-respiratory	NN	<unknown>
cares	VBZ	care
during	IN	during
the	DT	the
first	JJ	first
months	NNS	month
of	IN	of
treatment	NN	treatment
and	CC	and
preventing	VBG	prevent
infection	NN	infection
especially	RB	especially
nosocomial	JJ	<unknown>
infections.⚫	JJ	<unknown>
</td>
<td class='article_abstract' colspan='2'>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
a	DT	a
rare	JJ	rare
metabolic	JJ	metabolic
disorder	NN	disorder
due	JJ	due
to	TO	to
lysosomal	JJ	lysosomal
alpha-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
deficiency	NN	deficiency
.	SENT	.
It	PP	it
is	VBZ	be
considered	VBN	consider
as	IN	as
a	DT	a
multi-systemic	JJ	<unknown>
disease	NN	disease
since	IN	since
,	,	,
although	IN	although
glycogen	NN	glycogen
accumulation	NN	accumulation
is	VBZ	be
largely	RB	largely
prominent	JJ	prominent
in	IN	in
heart	NN	heart
,	,	,
skeletal	JJ	skeletal
and	CC	and
respiratory	JJ	respiratory
muscles	NNS	muscle
,	,	,
other	JJ	other
organs	NNS	organ
can	MD	can
also	RB	also
be	VB	be
affected	VBN	affect
.	SENT	.
As	RB	as
regards	VBZ	regard
the	DT	the
vascular	JJ	vascular
system	NN	system
,	,	,
few	JJ	few
reports	NNS	report
have	VBP	have
documented	VBN	document
cerebrovascular	JJ	cerebrovascular
malformations	NNS	malformation
in	IN	in
Pompe	NP	<unknown>
patients	NNS	patient
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
define	VB	define
the	DT	the
presence	NN	presence
and	CC	and
type	NN	type
of	IN	of
intracranial	JJ	intracranial
<span class='symptom'>
arterial	JJ	arterial
abnormalities	NNS	abnormality
</span>
in	IN	in
a	DT	a
cohort	NN	cohort
of	IN	of
late	JJ	late
onset	NN	onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
(	(	(
LOPD	JJ	<unknown>
)	)	)
patients.We	NNS	<unknown>
have	VBP	have
studied	VBN	study
21	CD	@card@
LOPD	JJ	<unknown>
patients	NNS	patient
with	IN	with
cerebral	JJ	cerebral
CT	NP	CT
angiography	NN	angiography
(	(	(
CTA	NP	CTA
)	)	)
,	,	,
using	VBG	use
maximum	JJ	maximum
intensity	NN	intensity
projection	NN	projection
and	CC	and
volume	NN	volume
rendering	NN	rendering
technique	NN	technique
for	IN	for
3D-image	JJ	<unknown>
reconstruction.We	NNS	<unknown>
found	VBD	find
intracranial	JJ	intracranial
<span class='symptom'>
arterial	JJ	arterial
abnormalities	NNS	abnormality
</span>
in	IN	in
13/21	CD	@card@
patients	NNS	patient
(	(	(
62	CD	@card@
%	NN	%
)	)	)
,	,	,
of	IN	of
whom	WP	whom
:	:	:
2/21	CD	@card@
patients	NNS	patient
(	(	(
9.5	CD	@card@
%	NN	%
)	)	)
showed	VBD	show
an	DT	an
unruptured	JJ	<unknown>
<span class='symptom'>
intracranial	JJ	intracranial
aneurysm	NN	aneurysm
</span>
(	(	(
respectively	RB	respectively
2	CD	2
and	CC	and
4	CD	4
mm	NN	mm.
)	)	)
,	,	,
10/21	CD	@card@
(	(	(
47	CD	@card@
%	NN	%
)	)	)
had	VBD	have
a	DT	a
vertebrobasilar	JJ	<unknown>
dolichoectasia	NN	<unknown>
(	(	(
VBD	NP	<unknown>
)	)	)
and	CC	and
1/21	CD	@card@
a	DT	a
basilar	JJ	basilar
artery	NN	artery
fenestration	NN	fenestration
.	SENT	.
Signs	NNS	sign
of	IN	of
lacunar	JJ	lacunar
<span class='symptom'>
encephalopathy	NN	<unknown>
</span>
(	(	(
insular	JJ	insular
,	,	,
capsular	NN	capsular
and	CC	and
frontal	JJ	frontal
subcortical	JJ	subcortical
lesions	NNS	lesion
)	)	)
were	VBD	be
detected	VBN	detect
in	IN	in
13/21	CD	@card@
patients	NNS	patient
(	(	(
62	CD	@card@
%	NN	%
)	)	)
and	CC	and
this	DT	this
correlated	VBN	correlate
with	IN	with
the	DT	the
presence	NN	presence
of	IN	of
<span class='symptom'>
respiratory	JJ	respiratory
impairment	NN	impairment
</span>
(	(	(
p	NN	p
=	SYM	=
0.017).These	JJ	<unknown>
findings	NNS	finding
differ	VBP	differ
from	IN	from
what	WP	what
has	VBZ	have
been	VBN	be
previously	RB	previously
observed	VBN	observe
in	IN	in
healthy	JJ	healthy
,	,	,
aged-matched	JJ	<unknown>
populations	NNS	population
and	CC	and
confirm	VBP	confirm
that	IN	that
cerebral	JJ	cerebral
arteries	NNS	artery
abnormalities	NNS	abnormality
,	,	,
mainly	RB	mainly
involving	VBG	involve
the	DT	the
posterior	JJ	posterior
circle	NN	circle
,	,	,
are	VBP	be
not	RB	not
so	RB	so
rare	JJ	rare
in	IN	in
LOPD	JJ	<unknown>
patients	NNS	patient
and	CC	and
are	VBP	be
often	RB	often
accompanied	VBN	accompany
by	IN	by
a	DT	a
lacunar	JJ	lacunar
<span class='symptom'>
encephalopathy	NN	<unknown>
</span>
that	WDT	that
might	MD	might
represent	VB	represent
a	DT	a
hypoxic-ischemic	JJ	<unknown>
origin	NN	origin
.	SENT	.
A	DT	a
CTA	NP	CTA
or	CC	or
an	DT	an
MRA	NP	<unknown>
is	VBZ	be
recommended	VBN	recommend
,	,	,
in	IN	in
LOPD	JJ	<unknown>
patients	NNS	patient
,	,	,
for	IN	for
early	JJ	early
detection	NN	detection
of	IN	of
cerebrovascular	JJ	cerebrovascular
malformations	NNS	malformation
as	IN	as
they	PP	they
could	MD	could
lead	VB	lead
to	TO	to
life-threatening	JJ	life-threatening
events	NNS	event
such	JJ	such
as	IN	as
sub-arachnoid	JJ	<unknown>
haemorrhage	NN	haemorrhage
or	CC	or
brainstem	NN	<unknown>
compression.⚫	NN	<unknown>
</td>
<td class='article_abstract' colspan='2'>
Late-onset	NN	late-onset
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
(	(	(
LOPD	NP	<unknown>
)	)	)
is	VBZ	be
a	DT	a
rare	JJ	rare
treatable	JJ	treatable
lysosomal	JJ	lysosomal
storage	NN	storage
disorder	NN	disorder
characterized	VBN	characterize
by	IN	by
progressive	JJ	progressive
lysosomal	JJ	lysosomal
glycogen	NN	glycogen
accumulation	NN	accumulation
and	CC	and
<span class='symptom'>
muscle	NN	muscle
weakness	NN	weakness
</span>
,	,	,
with	IN	with
often	RB	often
a	DT	a
limb-girdle	NN	<unknown>
pattern	NN	pattern
.	SENT	.
Despite	IN	despite
published	VBN	publish
guidelines	NNS	guideline
,	,	,
testing	VBG	test
for	IN	for
LOPD	NN	<unknown>
is	VBZ	be
often	RB	often
overlooked	VBN	overlook
or	CC	or
delayed	VBN	delay
in	IN	in
adults	NNS	adult
,	,	,
owing	VBG	owe
to	TO	to
its	PP$	its
low	JJ	low
frequency	NN	frequency
compared	VBN	compare
to	TO	to
other	JJ	other
muscle	NN	muscle
disorders	NNS	disorder
with	IN	with
similar	JJ	similar
muscle	NN	muscle
patterns	NNS	pattern
.	SENT	.
Next-generation	NN	next-generation
sequencing	NP	sequencing
has	VBZ	have
the	DT	the
capability	NN	capability
to	TO	to
test	VB	test
concurrently	RB	concurrently
for	IN	for
several	JJ	several
muscle	NN	muscle
disorders	NNS	disorder
.	SENT	.
This	DT	this
could	MD	could
potentially	RB	potentially
lead	VB	lead
to	TO	to
increased	VBN	increase
diagnosis	NN	diagnosis
of	IN	of
LOPD	NP	<unknown>
,	,	,
disorders	NNS	disorder
with	IN	with
non-specific	JJ	<unknown>
<span class='symptom'>
muscle	NN	muscle
weakness	NN	weakness
</span>
or	CC	or
atypical	JJ	atypical
patients.We	NNS	<unknown>
developed	VBD	develop
a	DT	a
gene	NN	gene
panel	NN	panel
to	TO	to
further	RBR	further
study	VB	study
its	PP$	its
clinical	JJ	clinical
utility	NN	utility
in	IN	in
a	DT	a
cohort	NN	cohort
of	IN	of
patients	NNS	patient
with	IN	with
suspected	JJ	suspected
muscle	NN	muscle
disorders	NNS	disorder
.	SENT	.
We	PP	we
designed	VBD	design
a	DT	a
gene	NN	gene
panel	NN	panel
to	TO	to
analyze	VB	analyze
the	DT	the
coding	VBG	code
sequences	NNS	sequence
and	CC	and
splice	NN	splice
site	NN	site
junctions	NNS	junction
of	IN	of
<span class='gene'>
GAA	NP	<unknown>
</span>
causing	VBG	cause
LOPD	NN	<unknown>
,	,	,
along	RB	along
with	IN	with
77	CD	@card@
other	JJ	other
genes	NNS	gene
causing	VBG	cause
muscle	NN	muscle
disorders	NNS	disorder
with	IN	with
overlapping	JJ	overlapping
phenotypes.At	NN	<unknown>
a	DT	a
median	JJ	median
coverage	NN	coverage
of	IN	of
~200X	NN	<unknown>
(	(	(
sequences	NNS	sequence
per	IN	per
base	NN	base
)	)	)
,	,	,
all	DT	all
<span class='gene'>
GAA	NP	<unknown>
</span>
exons	NNS	exon
were	VBD	be
successfully	RB	successfully
covered	VBN	cover
with	IN	with
>20X	NN	<unknown>
and	CC	and
only	RB	only
0.3	CD	@card@
%	NN	%
of	IN	of
exons	NNS	exon
across	IN	across
all	DT	all
genes	NNS	gene
were	VBD	be
<20X	NN	<unknown>
.	SENT	.
The	DT	the
panel	NN	panel
showed	VBD	show
an	DT	an
excellent	JJ	excellent
sensitivity	NN	sensitivity
(	(	(
100	CD	@card@
%	NN	%
)	)	)
and	CC	and
specificity	NN	specificity
(	(	(
98	CD	@card@
%	NN	%
)	)	)
across	IN	across
all	DT	all
selected	JJ	selected
genes	NNS	gene
,	,	,
using	VBG	use
known	VBN	know
variations	NNS	variation
in	IN	in
Pompe	NP	<unknown>
patients	NNS	patient
and	CC	and
controls	NNS	control
.	SENT	.
We	PP	we
determined	VBD	determine
its	PP$	its
clinical	JJ	clinical
utility	NN	utility
by	IN	by
analyzing	VBG	analyze
34	CD	@card@
patients	NNS	patient
with	IN	with
suspected	JJ	suspected
muscle	NN	muscle
disorders	NNS	disorder
of	IN	of
undetermined	JJ	undetermined
etiology	NN	etiology
and	CC	and
various	JJ	various
muscle	NN	muscle
patterns	NNS	pattern
,	,	,
who	WP	who
were	VBD	be
referred	VBN	refer
or	CC	or
followed	VBN	follow
in	IN	in
neuromuscular	JJ	neuromuscular
and	CC	and
genetics	NN	genetics
clinics	NNS	clinic
.	SENT	.
A	DT	a
putative	JJ	putative
diagnosis	NN	diagnosis
was	VBD	be
found	VBN	find
in	IN	in
up	IN	up
to	TO	to
32	CD	@card@
%	NN	%
of	IN	of
patients	NNS	patient
.	SENT	.
The	DT	the
gene	NN	gene
panel	NN	panel
was	VBD	be
instrumental	JJ	instrumental
in	IN	in
reaching	VBG	reach
a	DT	a
diagnosis	NN	diagnosis
in	IN	in
atypical	JJ	atypical
patients	NNS	patient
,	,	,
including	VBG	include
one	CD	one
LOPD	NN	<unknown>
case	NN	case
.	SENT	.
Acid	JJ	acid
alpha-glucosidase	NN	<unknown>
activity	NN	activity
was	VBD	be
used	VBN	use
to	TO	to
confirm	VB	confirm
the	DT	the
molecular	JJ	molecular
results	NNS	result
in	IN	in
all	DT	all
patients.This	NN	<unknown>
work	NN	work
highlights	VBZ	highlight
the	DT	the
high	JJ	high
clinical	JJ	clinical
utility	NN	utility
of	IN	of
gene	NN	gene
panels	NNS	panel
in	IN	in
patients	NNS	patient
with	IN	with
suspected	JJ	suspected
muscle	NN	muscle
disorders	NNS	disorder
and	CC	and
its	PP$	its
potential	NN	potential
to	TO	to
facilitate	VB	facilitate
the	DT	the
diagnosis	NN	diagnosis
of	IN	of
patients	NNS	patient
showing	VBG	show
non-specific	JJ	<unknown>
<span class='symptom'>
muscle	NN	muscle
weakness	NN	weakness
</span>
or	CC	or
atypical	JJ	atypical
phenotypes	NNS	phenotype
.	SENT	.
We	PP	we
propose	VBP	propose
that	IN	that
gene	NN	gene
panels	NNS	panel
should	MD	should
be	VB	be
used	VBN	use
as	IN	as
a	DT	a
first-tier	NN	first-tier
test	NN	test
in	IN	in
patients	NNS	patient
with	IN	with
suspected	JJ	suspected
muscle	NN	muscle
disorders	NNS	disorder
of	IN	of
undetermined	JJ	undetermined
etiology	NN	etiology
,	,	,
which	WDT	which
could	MD	could
further	RBR	further
increase	VB	increase
overall	JJ	overall
diagnosis	NN	diagnosis
of	IN	of
muscle	NN	muscle
conditions	NNS	condition
,	,	,
and	CC	and
potentially	RB	potentially
reduce	VB	reduce
diagnostic	JJ	diagnostic
delay	NN	delay
.	SENT	.
Further	JJR	further
studies	NNS	study
are	VBP	be
necessary	JJ	necessary
to	TO	to
determine	VB	determine
the	DT	the
<span class='gene'>
impact	NN	impact
</span>
of	IN	of
first-tier	NN	first-tier
gene	NN	gene
panels	NNS	panel
on	IN	on
diagnostic	JJ	diagnostic
delay	NN	delay
and	CC	and
on	IN	on
treatment	NN	treatment
outcome	NN	outcome
for	IN	for
LOPD.⚫	NP	<unknown>
</td>
<td class='article_abstract' colspan='2'>
We	PP	we
report	VBP	report
a	DT	a
patient	NN	patient
in	IN	in
whom	WP	whom
the	DT	the
diagnosis	NN	diagnosis
of	IN	of
a	DT	a
treatable	JJ	treatable
disease	NN	disease
was	VBD	be
delayed	VBN	delay
for	IN	for
30	CD	@card@
years.Recent	JJ	<unknown>
discoveries	NNS	discovery
of	IN	of
next	JJ	next
generation	NN	generation
sequencing	NP	sequencing
(	(	(
NGS	NP	<unknown>
)	)	)
have	VBP	have
allowed	VBN	allow
us	PP	us
to	TO	to
reconsider	VB	reconsider
the	DT	the
diagnosis	NN	diagnosis
of	IN	of
limb	NN	limb
girdle	NN	girdle
<span class='symptom'>
muscular	JJ	muscular
dystrophy	NN	dystrophy
</span>
(	(	(
LGMD	JJ	<unknown>
)	)	)
cases	NNS	case
of	IN	of
unknown	JJ	unknown
etiology.A	NN	<unknown>
36-year	JJ	<unknown>
old	JJ	old
man	NN	man
appeared	VBD	appear
to	TO	to
have	VB	have
LGMD	NN	<unknown>
with	IN	with
onset	NN	onset
in	IN	in
shoulder	NN	shoulder
girdle	NN	girdle
muscles	NNS	muscle
,	,	,
but	CC	but
all	DT	all
sarcolemmal	JJ	<unknown>
and	CC	and
cytoskeletal	JJ	<unknown>
proteins	NNS	protein
tested	VBN	test
by	IN	by
immunoblotting	NN	<unknown>
and	CC	and
immunohistochemistry	NN	<unknown>
gave	VBD	give
normal	JJ	normal
results	NNS	result
.	SENT	.
He	PP	he
developed	VBD	develop
<span class='symptom'>
respiratory	JJ	respiratory
insufficiency	NN	insufficiency
</span>
and	CC	and
became	VBD	become
dependent	JJ	dependent
on	IN	on
overnight	JJ	overnight
ventilation	NN	ventilation
at	IN	at
age	NN	age
44	CD	@card@
.	SENT	.
By	IN	by
NGS	NP	<unknown>
technology	NN	technology
,	,	,
2	CD	2
mutations	NNS	mutation
in	IN	in
the	DT	the
<span class='gene'>
GAA	NP	<unknown>
</span>
gene	NN	gene
(	(	(
IVS1	NP	<unknown>
and	CC	and
a	DT	a
missense	NN	<unknown>
mutation	NN	mutation
in	IN	in
exon	NN	exon
11	CD	@card@
)	)	)
allowed	VBD	allow
us	PP	us
to	TO	to
make	VB	make
a	DT	a
definite	JJ	definite
diagnosis	NN	diagnosis
of	IN	of
glycogenosis	NN	<unknown>
type	NN	type
II	NP	II
(	(	(
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
)	)	)
and	CC	and
start	VB	start
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
at	IN	at
age	NN	age
71.Mild	JJ	<unknown>
non-dystrophic	JJ	<unknown>
features	NNS	feature
on	IN	on
muscle	NN	muscle
biopsy	NN	biopsy
and	CC	and
respiratory	JJ	respiratory
muscle	NN	muscle
involvement	NN	involvement
should	MD	should
suggest	VB	suggest
late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
in	IN	in
patients	NNS	patient
with	IN	with
an	DT	an
unclassified	JJ	unclassified
LGMD	NN	<unknown>
phenotype	NN	phenotype
.	SENT	.
NGS	NNS	<unknown>
may	MD	may
help	VB	help
make	VB	make
the	DT	the
diagnosis	NN	diagnosis
.	SENT	.
This	DT	this
article	NN	article
is	VBZ	be
protected	VBN	protect
by	IN	by
copyright	NN	copyright
.	SENT	.
All	DT	all
rights	NNS	right
reserved.⚫	NN	<unknown>
</td>
<td class='article_abstract' colspan='2'>
In	IN	in
patients	NNS	patient
with	IN	with
Late-Onset	NN	late-onset
<span class='disease'>
Pompe	NP	<unknown>
Disease	NP	Disease
</span>
(	(	(
LOPD	NP	<unknown>
)	)	)
,	,	,
progressive	JJ	progressive
respiratory	JJ	respiratory
muscle	NN	muscle
involvement	NN	involvement
leads	VBZ	lead
to	TO	to
reduced	VBN	reduce
pulmonary	JJ	pulmonary
function	NN	function
,	,	,
with	IN	with
<span class='symptom'>
respiratory	JJ	respiratory
failure	NN	failure
</span>
the	DT	the
most	RBS	most
common	JJ	common
cause	NN	cause
of	IN	of
mortality	NN	mortality
.	SENT	.
Early	JJ	early
disease	NN	disease
manifestations	NNS	manifestation
include	VBP	include
sleep-disordered	JJ	<unknown>
breathing	NN	breathing
,	,	,
which	WDT	which
can	MD	can
be	VB	be
treated	VBN	treat
with	IN	with
non-invasive	JJ	non-invasive
ventilation	NN	ventilation
;	:	;
however	RB	however
,	,	,
progressive	JJ	progressive
diurnal	JJ	diurnal
deficits	NNS	deficit
can	MD	can
require	VB	require
invasive	JJ	invasive
ventilation	NN	ventilation
.	SENT	.
To	TO	To
determine	VB	determine
if	IN	if
pulmonary	JJ	pulmonary
function	NN	function
tests	NNS	test
(	(	(
PFTs	NP	<unknown>
)	)	)
predict	VBP	predict
the	DT	the
thresholds	NNS	threshold
for	IN	for
ventilation	NN	ventilation
and	CC	and
wheelchair	NN	wheelchair
use	NN	use
,	,	,
a	DT	a
systematic	JJ	systematic
literature	NN	literature
review	NN	review
identified	VBD	identify
cross-sectional	JJ	cross-sectional
clinical	JJ	clinical
patient	JJ	patient
data	NNS	datum
(	(	(
N	NP	N
=	SYM	=
174	CD	@card@
)	)	)
that	WDT	that
was	VBD	be
classified	VBN	classify
into	IN	into
ventilation	NN	ventilation
and	CC	and
wheelchair	NN	wheelchair
cohorts	NNS	cohort
.	SENT	.
PFTs	NNS	<unknown>
included	VBD	include
maximum	JJ	maximum
inspiratory	JJ	inspiratory
pressure	NN	pressure
(	(	(
<span class='gene'>
MIP	NP	<unknown>
</span>
)	)	)
,	,	,
maximum	JJ	maximum
expiratory	JJ	expiratory
pressure	NN	pressure
(	(	(
MEP	NP	<unknown>
)	)	)
,	,	,
forced	VBN	force
vital	JJ	vital
capacity	NN	capacity
(	(	(
FVC	NP	<unknown>
)	)	)
,	,	,
and	CC	and
vital	JJ	vital
capacity	NN	capacity
(	(	(
VC	NP	VC
)	)	)
,	,	,
with	IN	with
vital	JJ	vital
capacities	NNS	capacity
measured	VBN	measure
in	IN	in
the	DT	the
upright	JJ	upright
(	(	(
-U	NN	<unknown>
)	)	)
and	CC	and
supine	JJ	supine
(	(	(
-S	NN	<unknown>
)	)	)
positions	NNS	position
.	SENT	.
Receiver	NN	receiver
operating	VBG	operate
characteristic	JJ	characteristic
(	(	(
ROC	NP	<unknown>
)	)	)
curves	NNS	curve
were	VBD	be
used	VBN	use
to	TO	to
calculate	VB	calculate
cut-points	NNS	<unknown>
(	(	(
<span class='gene'>
CP	NP	CP
</span>
)	)	)
and	CC	and
area	NN	area
under	IN	under
the	DT	the
curve	NN	curve
(AUC)	NN	<unknown>
.	SENT	.
For	IN	for
all	DT	all
ventilation	NN	ventilation
and	CC	and
mobility	NN	mobility
thresholds	NNS	threshold
tested	VBD	test
,	,	,
ROC	NP	<unknown>
analyses	NNS	analysis
demonstrated	VBD	demonstrate
AUC	NP	<unknown>
values	NNS	value
from	IN	from
86-89	CD	@card@
%	NN	%
for	IN	for
<span class='gene'>
MIP	NP	<unknown>
</span>
,	,	,
72-96	CD	@card@
%	NN	%
for	IN	for
MEP	NN	<unknown>
,	,	,
and	CC	and
74-96	CD	@card@
%	NN	%
for	IN	for
all	DT	all
vital	JJ	vital
capacity	NN	capacity
metrics	NNS	metric
.	SENT	.
Thus	RB	thus
,	,	,
PFTs	NNS	<unknown>
are	VBP	be
useful	JJ	useful
in	IN	in
predicting	VBG	predict
the	DT	the
thresholds	NNS	threshold
for	IN	for
nighttime	NN	nighttime
ventilation	NN	ventilation
,	,	,
daytime	JJ	daytime
ventilation	NN	ventilation
,	,	,
and	CC	and
wheelchair	NN	wheelchair
use	NN	use
,	,	,
with	IN	with
<span class='gene'>
MIP	NP	<unknown>
</span>
and	CC	and
VC-U	NP	<unknown>
having	VBG	have
both	DT	both
high	JJ	high
AUC	NP	<unknown>
values	NNS	value
and	CC	and
consistency	NN	consistency
.	SENT	.
The	DT	the
PFT	NP	<unknown>
mobility	NN	mobility
CPs	NNS	<unknown>
were	VBD	be
low	JJ	low
(	(	(
<span class='gene'>
MIP	NP	<unknown>
</span>
CP	NP	CP
=	SYM	=
0.9	CD	@card@
kPa	NN	<unknown>
,	,	,
MEP	NP	<unknown>
,	,	,
CP	NP	CP
=	SYM	=
2.6	CD	@card@
kPa	NN	<unknown>
,	,	,
VC-U	NP	<unknown>
CP	NP	CP
=	SYM	=
19	CD	@card@
%	NN	%
predicted	VBN	predict
)	)	)
,	,	,
suggesting	VBG	suggest
an	DT	an
endurance	NN	endurance
component	NN	component
associated	VBN	associate
with	IN	with
wheelchair	NN	wheelchair
use.⚫	NN	<unknown>
</td>
<td class='article_abstract' colspan='2'>
Elevated	JJ	elevated
plasma	NN	plasma
cardiac	JJ	cardiac
troponin	NN	<unknown>
<span class='gene'>
T	NN	T
</span>
(	(	(
cTnT	NN	<unknown>
)	)	)
levels	NNS	level
in	IN	in
patients	NNS	patient
with	IN	with
neuromuscular	JJ	neuromuscular
disorders	NNS	disorder
may	MD	may
erroneously	RB	erroneously
lead	VB	lead
to	TO	to
the	DT	the
diagnosis	NN	diagnosis
of	IN	of
acute	JJ	acute
<span class='symptom'>
myocardial	JJ	myocardial
infarction	NN	infarction
</span>
or	CC	or
myocardial	JJ	myocardial
injury.In	NN	<unknown>
122	CD	@card@
patients	NNS	patient
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
the	DT	the
relationship	NN	relationship
between	IN	between
cTnT	NN	<unknown>
,	,	,
cardiac	JJ	cardiac
troponin	NN	<unknown>
I	PP	I
,	,	,
creatine	NN	creatine
kinase	NN	kinase
(	(	(
CK	NP	CK
)	)	)
,	,	,
CK-myocardial	JJ	<unknown>
band	NN	band
levels	NNS	level
,	,	,
and	CC	and
skeletal	JJ	skeletal
muscle	NN	muscle
damage	NN	damage
was	VBD	be
assessed	VBN	assess
.	SENT	.
ECG	NN	<unknown>
and	CC	and
echocardiography	NN	<unknown>
were	VBD	be
used	VBN	use
to	TO	to
evaluate	VB	evaluate
possible	JJ	possible
cardiac	JJ	cardiac
disease	NN	disease
.	SENT	.
Patients	NNS	patient
were	VBD	be
divided	VBN	divide
into	IN	into
classic	JJ	classic
infantile	JJ	infantile
,	,	,
childhood-onset	NN	<unknown>
,	,	,
and	CC	and
adult-onset	NN	<unknown>
patients	NNS	patient
.	SENT	.
cTnT	NN	<unknown>
levels	NNS	level
were	VBD	be
elevated	VBN	elevate
in	IN	in
82	CD	@card@
%	NN	%
of	IN	of
patients	NNS	patient
(	(	(
median	NN	median
27	CD	@card@
ng/L	NNS	<unknown>
,	,	,
normal	JJ	normal
values	NNS	value
<14	NN	<unknown>
ng/L)	NNS	<unknown>
.	SENT	.
Cardiac	JJ	cardiac
troponin	NN	<unknown>
I	NN	I
levels	NNS	level
were	VBD	be
normal	JJ	normal
in	IN	in
all	DT	all
patients	NNS	patient
,	,	,
whereas	IN	whereas
CK-myocardial	JJ	<unknown>
band	NN	band
levels	NNS	level
were	VBD	be
increased	VBN	increase
in	IN	in
59	CD	@card@
%	NN	%
of	IN	of
patients	NNS	patient
.	SENT	.
cTnT	NN	<unknown>
levels	NNS	level
correlated	VBN	correlate
with	IN	with
CK	NP	CK
levels	NNS	level
in	IN	in
all	DT	all
3	CD	3
subgroups	NNS	subgroup
(P<0.001)	JJ	<unknown>
.	SENT	.
None	NN	none
of	IN	of
the	DT	the
abnormal	JJ	abnormal
ECGs	NNS	<unknown>
recorded	VBN	record
in	IN	in
21	CD	@card@
patients	NNS	patient
were	VBD	be
indicative	JJ	indicative
of	IN	of
acute	JJ	acute
<span class='symptom'>
myocardial	JJ	myocardial
infarction	NN	infarction
</span>
,	,	,
and	CC	and
there	EX	there
were	VBD	be
no	DT	no
differences	NNS	difference
in	IN	in
cTnT	NN	<unknown>
levels	NNS	level
between	IN	between
patients	NNS	patient
with	IN	with
and	CC	and
without	IN	without
(	(	(
n=90	NN	<unknown>
)	)	)
abnormalities	NNS	abnormality
on	IN	on
ECG	NP	<unknown>
(	(	(
median	NN	median
28	CD	@card@
ng/L	NNS	<unknown>
in	IN	in
both	DT	both
groups)	NN	<unknown>
.	SENT	.
The	DT	the
median	NN	median
left	VBD	leave
ventricular	JJ	ventricular
mass	NN	mass
index	NN	index
measured	VBN	measure
with	IN	with
echocardiography	NN	<unknown>
was	VBD	be
normal	JJ	normal
in	IN	in
all	PDT	all
the	DT	the
3	CD	3
subgroups	NNS	subgroup
.	SENT	.
cTnT	NN	<unknown>
mRNA	NN	<unknown>
expression	NN	expression
in	IN	in
skeletal	JJ	skeletal
muscle	NN	muscle
was	VBD	be
not	RB	not
detectable	JJ	detectable
in	IN	in
controls	NNS	control
but	CC	but
was	VBD	be
strongly	RB	strongly
induced	VBN	induce
in	IN	in
patients	NNS	patient
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
cTnT	NN	<unknown>
protein	NN	protein
was	VBD	be
identified	VBN	identify
by	IN	by
mass	JJ	mass
spectrometry	NN	spectrometry
in	IN	in
patient-derived	JJ	<unknown>
skeletal	JJ	skeletal
muscle	NN	muscle
tissue.Elevated	JJ	<unknown>
plasma	NN	plasma
cTnT	NN	<unknown>
levels	NNS	level
in	IN	in
patients	NNS	patient
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
are	VBP	be
associated	VBN	associate
with	IN	with
skeletal	JJ	skeletal
muscle	NN	muscle
damage	NN	damage
,	,	,
rather	RB	rather
than	IN	than
acute	JJ	acute
myocardial	JJ	myocardial
injury	NN	injury
.	SENT	.
Increased	VBN	increase
cTnT	NN	<unknown>
levels	NNS	level
in	IN	in
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
and	CC	and
likely	JJ	likely
other	JJ	other
neuromuscular	JJ	neuromuscular
disorders	NNS	disorder
should	MD	should
be	VB	be
interpreted	VBN	interpret
with	IN	with
caution	NN	caution
to	TO	to
avoid	VB	avoid
unnecessary	JJ	unnecessary
cardiac	JJ	cardiac
interventions.⚫	NN	<unknown>
</td>
<td class='article_abstract' colspan='2'>
Though	IN	though
enzyme-replacement	NN	<unknown>
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
with	IN	with
alglucosidase	NN	<unknown>
alfa	NN	<unknown>
has	VBZ	have
significantly	RB	significantly
improved	VBN	improve
the	DT	the
prospects	NNS	prospect
for	IN	for
patients	NNS	patient
with	IN	with
classic	JJ	classic
infantile	JJ	infantile
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
some	DT	some
50	CD	@card@
%	NN	%
of	IN	of
treated	VBN	treat
infants	NNS	infant
do	VBP	do
not	RB	not
survive	VB	survive
ventilator-free	JJ	<unknown>
beyond	IN	beyond
the	DT	the
age	NN	age
of	IN	of
3	CD	3
years	NNS	year
.	SENT	.
We	PP	we
investigated	VBD	investigate
whether	IN	whether
higher	JJR	high
and	CC	and
more	JJR	more
frequent	JJ	frequent
dosing	VBG	dose
of	IN	of
alglucosidase	NN	<unknown>
alfa	NN	<unknown>
improves	VBZ	improve
outcome.Eight	JJ	<unknown>
cross-reactive	JJ	<unknown>
immunological	JJ	immunological
material	NN	material
(	(	(
CRIM	NP	Crim
)	)	)
positive	JJ	positive
patients	NNS	patient
were	VBD	be
included	VBN	include
in	IN	in
the	DT	the
study	NN	study
.	SENT	.
All	DT	all
had	VBD	have
fully	RB	fully
deleterious	JJ	deleterious
mutations	NNS	mutation
in	IN	in
both	DT	both
<span class='gene'>
GAA	NP	<unknown>
</span>
alleles	NNS	allele
.	SENT	.
Four	NP	Four
received	VBD	receive
a	DT	a
dose	NN	dose
of	IN	of
20	CD	@card@
mg/kg	NN	<unknown>
every	DT	every
other	JJ	other
week	NN	week
(	(	(
eow	NN	<unknown>
)	)	)
and	CC	and
four	CD	four
received	VBD	receive
40	CD	@card@
mg/kg/week	NN	<unknown>
.	SENT	.
Survival	NN	survival
,	,	,
ventilator-free	JJ	<unknown>
survival	NN	survival
,	,	,
left-ventricular	JJ	<unknown>
mass	JJ	mass
index	NN	index
(	(	(
LVMI	NP	<unknown>
)	)	)
,	,	,
motor	NN	motor
outcome	NN	outcome
,	,	,
infusion-associated	JJ	<unknown>
reactions	NNS	reaction
(	(	(
IARs	NP	<unknown>
)	)	)
,	,	,
and	CC	and
antibody	NN	antibody
formation	NN	formation
were	VBD	be
evaluated.All	JJ	<unknown>
eight	CD	eight
patients	NNS	patient
were	VBD	be
alive	JJ	alive
at	IN	at
study	NN	study
end	NN	end
,	,	,
seven	CD	seven
of	IN	of
them	PP	them
remained	VBD	remain
ventilator-free	JJ	<unknown>
.	SENT	.
The	DT	the
patient	NN	patient
who	WP	who
became	VBD	become
ventilator	NN	ventilator
dependent	NN	dependent
was	VBD	be
treated	VBN	treat
with	IN	with
20	CD	@card@
mg/kg	NN	<unknown>
eow	NN	<unknown>
.	SENT	.
Three	CD	Three
of	IN	of
the	DT	the
four	CD	four
patients	NNS	patient
receiving	VBG	receive
20	CD	@card@
mg/kg	NN	<unknown>
eow	NN	<unknown>
learned	VBD	learn
to	TO	to
walk	VB	walk
;	:	;
two	CD	two
of	IN	of
them	PP	them
maintained	VBD	maintain
this	DT	this
ability	NN	ability
at	IN	at
study	NN	study
end	NN	end
.	SENT	.
All	DT	all
four	CD	four
patients	NNS	patient
receiving	VBG	receive
40	CD	@card@
mg/kg/week	NN	<unknown>
acquired	VBD	acquire
and	CC	and
maintained	VBD	maintain
the	DT	the
ability	NN	ability
to	TO	to
walk	VB	walk
at	IN	at
study	NN	study
end	NN	end
(	(	(
ages	NNS	age
of	IN	of
3.3-5.6	CD	@card@
years	NNS	year
)	)	)
,	,	,
even	RB	even
though	IN	though
their	PP$	their
baseline	JJ	baseline
motor	NN	motor
functioning	NN	functioning
was	VBD	be
poorer	JJR	poor
.	SENT	.
There	EX	there
were	VBD	be
no	DT	no
apparent	JJ	apparent
differences	NNS	difference
between	IN	between
the	DT	the
two	CD	two
dose	NN	dose
groups	NNS	group
with	IN	with
respect	NN	respect
to	TO	to
the	DT	the
effect	NN	effect
of	IN	of
ERT	NN	ERT
on	IN	on
LVMI	NP	<unknown>
,	,	,
the	DT	the
number	NN	number
of	IN	of
IARs	NNS	<unknown>
and	CC	and
antibody	NN	antibody
formation.Our	NN	<unknown>
data	NNS	datum
may	MD	may
suggest	VB	suggest
that	IN	that
a	DT	a
dose	NN	dose
of	IN	of
40	CD	@card@
mg/kg/week	NN	<unknown>
improves	VBZ	improve
outcome	NN	outcome
of	IN	of
CRIM	NP	Crim
positive	JJ	positive
patients	NNS	patient
over	IN	over
that	WDT	that
brought	VBD	bring
by	IN	by
the	DT	the
currently	RB	currently
recommended	VBN	recommend
dose	NN	dose
of	IN	of
20	CD	@card@
mg/kg	NN	<unknown>
eow	NN	<unknown>
.	SENT	.
Larger	JJR	large
studies	NNS	study
are	VBP	be
needed	VBN	need
to	TO	to
draw	VB	draw
definite	JJ	definite
conclusions.⚫	JJ	<unknown>
</td>
<td class='article_abstract' colspan='2'>
Quantitation	NN	<unknown>
of	IN	of
alpha-glucosidase	NN	<unknown>
(	(	(
α-GD	NN	<unknown>
)	)	)
activity	NN	activity
is	VBZ	be
of	IN	of
significance	NN	significance
to	TO	to
diagnosis	NN	diagnosis
of	IN	of
many	JJ	many
diseases	NNS	disease
including	VBG	include
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
and	CC	and
type	NN	type
II	NP	II
diabetes	NN	diabetes
.	SENT	.
We	PP	we
report	VBP	report
here	RB	here
a	DT	a
new	JJ	new
method	NN	method
to	TO	to
determine	VB	determine
α-GD	JJ	<unknown>
activity	NN	activity
using	VBG	use
matrix-assisted	JJ	<unknown>
laser	NN	laser
desorption/ionization	NN	<unknown>
(MALDI)-time-of-flight	NN	<unknown>
(	(	(
TOF	NP	<unknown>
)	)	)
mass	NN	mass
spectrometry	NN	spectrometry
(	(	(
MS	NN	Ms
)	)	)
in	IN	in
combination	NN	combination
with	IN	with
carbohydrate	NN	carbohydrate
microarray	NN	<unknown>
and	CC	and
affinity	NN	affinity
surface	NN	surface
chemistry	NN	chemistry
.	SENT	.
Carbohydrate	NN	carbohydrate
probes	NNS	probe
are	VBP	be
synthesized	VBN	synthesize
for	IN	for
capture	NN	capture
of	IN	of
the	DT	the
enzymatic	JJ	enzymatic
reaction	NN	reaction
products	NNS	product
and	CC	and
the	DT	the
adducts	VBZ	adduct
are	VBP	be
loaded	VBN	load
onto	IN	onto
a	DT	a
fluorinated	VBN	fluorinate
gold	NN	gold
surface	NN	surface
to	TO	to
generate	VB	generate
an	DT	an
array	NN	array
,	,	,
which	WDT	which
is	VBZ	be
followed	VBN	follow
by	IN	by
characterization	NN	characterization
by	IN	by
MALDI-TOF-MS	NP	<unknown>
.	SENT	.
The	DT	the
ratio	NN	ratio
of	IN	of
intensities	NNS	intensity
is	VBZ	be
used	VBN	use
to	TO	to
determine	VB	determine
the	DT	the
level	NN	level
of	IN	of
activity	NN	activity
of	IN	of
several	JJ	several
enzymes	NNS	enzyme
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
half	DT	half
maximal	JJ	maximal
inhibitory	JJ	inhibitory
concentration	NN	concentration
(	(	(
IC50	NP	<unknown>
)	)	)
of	IN	of
acarbose	NN	<unknown>
and	CC	and
epigallocatechin	NP	<unknown>
gallate	NP	gallate
are	VBP	be
also	RB	also
determined	VBN	determine
using	VBG	use
this	DT	this
approach	NN	approach
,	,	,
and	CC	and
the	DT	the
results	NNS	result
agree	VBP	agree
well	RB	well
with	IN	with
the	DT	the
reported	VBN	report
values	NNS	value
.	SENT	.
This	DT	this
method	NN	method
is	VBZ	be
advantageous	JJ	advantageous
as	RB	as
compared	VBN	compare
to	TO	to
conventional	JJ	conventional
colorimetric	JJ	colorimetric
techniques	NNS	technique
that	WDT	that
typically	RB	typically
suffer	VBP	suffer
matrix	NN	matrix
interference	NN	interference
problems	NNS	problem
from	IN	from
samples	NNS	sample
.	SENT	.
The	DT	the
use	NN	use
of	IN	of
the	DT	the
polyfluorinated	JJ	<unknown>
surface	NN	surface
has	VBZ	have
effectively	RB	effectively
suppressed	VBN	suppress
the	DT	the
interference	NN	interference
.	SENT	.
</td>
<td class='article_abstract' colspan='2'>
Adult	JJ	adult
Pompe	NP	<unknown>
disease/acid	NN	<unknown>
maltase	NN	maltase
deficiency	NN	deficiency
is	VBZ	be
an	DT	an
autosomal	JJ	autosomal
recessive	JJ	recessive
disorder	NN	disorder
resulting	VBG	result
in	IN	in
accumulation	NN	accumulation
of	IN	of
glycogen	NN	glycogen
in	IN	in
skeletal	JJ	skeletal
muscles	NNS	muscle
,	,	,
leading	VBG	lead
to	TO	to
<span class='symptom'>
myopathy	NN	<unknown>
</span>
frequently	RB	frequently
involving	VBG	involve
respiratory	JJ	respiratory
muscles	NNS	muscle
.	SENT	.
This	DT	this
involvement	NN	involvement
can	MD	can
cause	VB	cause
<span class='symptom'>
respiratory	JJ	respiratory
insufficiency	NN	insufficiency
</span>
that	WDT	that
may	MD	may
present	VB	present
as	IN	as
acute	JJ	acute
hypercapnic	JJ	<unknown>
<span class='symptom'>
respiratory	JJ	respiratory
failure	NN	failure
</span>
.	SENT	.
Enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
with	IN	with
alpha	NN	alpha
-	:	-
glucosidase	NN	<unknown>
alfa	NN	<unknown>
,	,	,
the	DT	the
only	JJ	only
disease-specific	JJ	<unknown>
treatment	NN	treatment
,	,	,
has	VBZ	have
been	VBN	be
available	JJ	available
as	IN	as
treatment	NN	treatment
option	NN	option
since	IN	since
2006	CD	@card@
.	SENT	.
ERT	NN	ERT
has	VBZ	have
shown	VBN	show
efficacy	NN	efficacy
concerning	VBG	concern
muscle	NN	muscle
strength	NN	strength
and	CC	and
pulmonary	JJ	pulmonary
function	NN	function
in	IN	in
adult	NN	adult
patients	NNS	patient
as	RB	as
well	RB	well
as	IN	as
positive	JJ	positive
association	NN	association
with	IN	with
survival	NN	survival
.	SENT	.
We	PP	we
present	VBP	present
two	CD	two
cases	NNS	case
where	WRB	where
addition	NN	addition
of	IN	of
ERT	NN	ERT
to	TO	to
Home	NP	Home
Mechanical	NP	Mechanical
Ventilation	NP	<unknown>
(	(	(
HMV	NP	<unknown>
)	)	)
showed	VBD	show
improvements	NNS	improvement
in	IN	in
lung	NN	lung
function	NN	function
and	CC	and
gas	NN	gas
exchange	NN	exchange
that	WDT	that
may	MD	may
not	RB	not
be	VB	be
entirely	RB	entirely
attributable	JJ	attributable
to	TO	to
nocturnal	JJ	nocturnal
HMV	NP	<unknown>
and	CC	and
therefore	RB	therefore
may	MD	may
further	RBR	further
indicate	VB	indicate
the	DT	the
beneficial	JJ	beneficial
role	NN	role
of	IN	of
ERT	NN	ERT
in	IN	in
conjunction	NN	conjunction
with	IN	with
HMV	NP	<unknown>
in	IN	in
Adult	NP	<unknown>
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
</td>
<td class='article_abstract' colspan='2'>
Lysosomal	JJ	lysosomal
storage	NN	storage
disorders	NNS	disorder
(	(	(
LSDs	NP	<unknown>
)	)	)
are	VBP	be
a	DT	a
group	NN	group
of	IN	of
>50	JJ	<unknown>
different	JJ	different
types	NNS	type
of	IN	of
inherited	VBN	inherit
metabolic	JJ	metabolic
disorders	NNS	disorder
that	WDT	that
result	VBP	result
from	IN	from
defects	NNS	defect
in	IN	in
the	DT	the
lysosome	NN	lysosome
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
investigate	VB	investigate
the	DT	the
distribution	NN	distribution
and	CC	and
demographic	JJ	demographic
characteristics	NNS	characteristic
of	IN	of
the	DT	the
different	JJ	different
subtypes	NNS	subtype
of	IN	of
LSDs	NP	<unknown>
in	IN	in
Eastern	NP	Eastern
China	NP	China
.	SENT	.
From	IN	from
2006	CD	@card@
to	TO	to
2012	CD	@card@
,	,	,
376	CD	@card@
out	IN	out
of	IN	of
1331	CD	@card@
clinically	RB	clinically
suspected	VBN	suspect
patients	NNS	patient
were	VBD	be
diagnosed	VBN	diagnose
with	IN	with
17	CD	@card@
different	JJ	different
subtypes	NNS	subtype
of	IN	of
LSDs	NP	<unknown>
at	IN	at
our	PP$	our
hospital	NN	hospital
.	SENT	.
Mucopolysaccharidoses	NP	<unknown>
(	(	(
MPS	NP	MPS
)	)	)
were	VBD	be
the	DT	the
most	RBS	most
common	JJ	common
group	NN	group
of	IN	of
LSDs	NP	<unknown>
(	(	(
50.5	CD	@card@
%	NN	%
)	)	)
,	,	,
followed	VBN	follow
by	IN	by
sphingolipidoses	NNS	<unknown>
(	(	(
25.4	CD	@card@
%	NN	%
)	)	)
and	CC	and
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
(19.8%)	NN	<unknown>
.	SENT	.
Mucolipidosis	NN	<unknown>
type	NN	type
II/III	NP	<unknown>
accounted	VBD	account
for	IN	for
the	DT	the
remaining	VBG	remain
4	CD	4
%	NN	%
of	IN	of
diagnosed	VBN	diagnose
LSDs	NP	<unknown>
.	SENT	.
MPS	NP	MPS
II	NP	II
was	VBD	be
the	DT	the
most	RBS	most
common	JJ	common
form	NN	form
of	IN	of
MPS	NP	MPS
,	,	,
comprising	VBG	comprise
47.4	CD	@card@
%	NN	%
of	IN	of
all	DT	all
MPS	NP	MPS
cases	NNS	case
diagnosed	VBD	diagnose
,	,	,
followed	VBN	follow
by	IN	by
MPS	NP	MPS
IVA	NP	Iva
(	(	(
26.8	CD	@card@
%	NN	%
)	)	)
and	CC	and
MPS	NP	MPS
I	NP	I
(16.3%)	NN	<unknown>
.	SENT	.
<span class='disease'>
Gaucher	JJR	gauche
disease	NN	disease
</span>
and	CC	and
Niemann-Pick	NP	<unknown>
disease	NN	disease
type	NN	type
A/B	NP	<unknown>
were	VBD	be
the	DT	the
two	CD	two
most	RBS	most
common	JJ	common
forms	NNS	form
of	IN	of
sphingolipidoses	NNS	<unknown>
.	SENT	.
There	EX	there
was	VBD	be
a	DT	a
large	JJ	large
variation	NN	variation
in	IN	in
the	DT	the
time	NN	time
between	IN	between
disease	NN	disease
onset	NN	onset
and	CC	and
eventual	JJ	eventual
diagnosis	NN	diagnosis
,	,	,
from	IN	from
0.3	CD	@card@
years	NNS	year
in	IN	in
infantile-onset	NN	<unknown>
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
to	TO	to
30	CD	@card@
years	NNS	year
in	IN	in
<span class='disease'>
Fabry	NP	Fabry
disease	NN	disease
</span>
,	,	,
highlighting	VBG	highlight
timely	JJ	timely
and	CC	and
accurate	JJ	accurate
diagnosis	NN	diagnosis
of	IN	of
LSDs	NP	<unknown>
as	IN	as
the	DT	the
main	JJ	main
challenge	NN	challenge
in	IN	in
China.Journal	NP	<unknown>
of	IN	of
Human	NP	Human
Genetics	NP	Genetics
advance	NN	advance
online	JJ	online
publication	NN	publication
,	,	,
7	CD	7
January	NP	January
2016	CD	@card@
;	:	;
doi:10.1038/jhg.2015.155	NN	<unknown>
.	SENT	.
</td>
<td class='article_abstract' colspan='2'>
Late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
,	,	,
for	IN	for
which	WDT	which
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
is	VBZ	be
available	JJ	available
,	,	,
induces	VBZ	induce
progressive	JJ	progressive
<span class='symptom'>
diaphragmatic	JJ	diaphragmatic
weakness	NN	weakness
</span>
.	SENT	.
Monitoring	VBG	monitor
diaphragmatic	JJ	diaphragmatic
function	NN	function
is	VBZ	be
therefore	RB	therefore
crucial	JJ	crucial
but	CC	but
is	VBZ	be
hindered	VBN	hinder
by	IN	by
the	DT	the
need	NN	need
to	TO	to
insert	VB	insert
esophageal	JJ	esophageal
and	CC	and
gastric	JJ	gastric
probes	NNS	probe
.	SENT	.
Vital	JJ	vital
capacity	NN	capacity
(	(	(
VC	NP	VC
)	)	)
,	,	,
inspiratory	JJ	inspiratory
capacity	NN	capacity
,	,	,
maximal	JJ	maximal
inspiratory	JJ	inspiratory
pressure	NN	pressure
,	,	,
and	CC	and
sniff	VB	sniff
nasal	JJ	nasal
pressure	NN	pressure
are	VBP	be
noninvasive	JJ	noninvasive
measurements	NNS	measurement
but	CC	but
reflect	VBP	reflect
only	RB	only
global	JJ	global
inspiratory-muscle	NN	<unknown>
function	NN	function
.	SENT	.
Diaphragmatic	JJ	diaphragmatic
function	NN	function
may	MD	may
be	VB	be
assessable	JJ	assessable
noninvasively	RB	<unknown>
based	VBN	base
on	IN	on
abdominal	JJ	abdominal
contribution	NN	contribution
to	TO	to
breathing	NN	breathing
and	CC	and
abdominal	JJ	abdominal
volume	NN	volume
change	NN	change
during	IN	during
the	DT	the
VC	NP	VC
maneuver	NN	maneuver
(	(	(
AVC-VC	NP	<unknown>
)	)	)
,	,	,
obtained	VBN	obtain
by	IN	by
3-dimensional	JJ	<unknown>
chest-wall	NN	<unknown>
analysis	NN	analysis
.	SENT	.
In	IN	in
11	CD	@card@
patients	NNS	patient
,	,	,
we	PP	we
assessed	VBD	assess
the	DT	the
relationships	NNS	relationship
between	IN	between
the	DT	the
above-listed	JJ	<unknown>
noninvasive	JJ	noninvasive
variables	NNS	variable
and	CC	and
the	DT	the
invasively	RB	<unknown>
measured	VBN	measure
Gilbert	NP	Gilbert
index	NN	index
reflecting	VBG	reflect
the	DT	the
diaphragmatic	JJ	diaphragmatic
contribution	NN	contribution
to	TO	to
breathing	VBG	breathe
(	(	(
ratio	NN	ratio
of	IN	of
gastric	JJ	gastric
pressure	NN	pressure
over	IN	over
transdiaphragmatic	JJ	<unknown>
pressure	NN	pressure
swings	NNS	swing
during	IN	during
spontaneous	JJ	spontaneous
breathing)	NN	<unknown>
.	SENT	.
Only	RB	only
abdominal	JJ	abdominal
contribution	NN	contribution
to	TO	to
breathing	NN	breathing
and	CC	and
AVC-VC	NP	<unknown>
correlated	VBD	correlate
significantly	RB	significantly
with	IN	with
the	DT	the
Gilbert	NP	Gilbert
index	NN	index
(	(	(
R	NP	R
=	SYM	=
0.977	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.0001	CD	@card@
;	:	;
and	CC	and
R	NP	R
=	SYM	=
0.944	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.001	CD	@card@
respectively)	NN	<unknown>
.	SENT	.
AVC-VC	NP	<unknown>
correlated	VBD	correlate
significantly	RB	significantly
with	IN	with
transdiaphragmatic	JJ	<unknown>
pressure	NN	pressure
swing	NN	swing
during	IN	during
the	DT	the
sniff	VBP	sniff
maneuver	NN	maneuver
(	(	(
R	NP	R
=	SYM	=
0.743	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.0009	CD	@card@
)	)	)
and	CC	and
with	IN	with
phrenic	JJ	phrenic
magnetic	JJ	magnetic
stimulation	NN	stimulation
(	(	(
R	NP	R
=	SYM	=
0.610	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.046)	JJ	<unknown>
.	SENT	.
Repeat	VB	repeat
testing	VBG	test
1	CD	1
year	NN	year
later	RBR	later
in	IN	in
the	DT	the
first	JJ	first
6	CD	6
patients	NNS	patient
showed	VBD	show
concordant	JJ	concordant
changes	NNS	change
in	IN	in
abdominal	JJ	abdominal
contribution	NN	contribution
to	TO	to
breathing	NN	breathing
,	,	,
Gilbert	NP	Gilbert
index	NN	index
,	,	,
and	CC	and
VC	NP	VC
.	SENT	.
Abdominal	JJ	abdominal
contribution	NN	contribution
to	TO	to
breathing	NN	breathing
and	CC	and
AVC-VC	NP	<unknown>
are	VBP	be
reliable	JJ	reliable
and	CC	and
noninvasive	JJ	noninvasive
indices	NN	indices
of	IN	of
diaphragmatic	JJ	diaphragmatic
function	NN	function
in	IN	in
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
and	CC	and
therefore	RB	therefore
hold	VB	hold
promise	NN	promise
as	IN	as
clinical	JJ	clinical
monitoring	NN	monitoring
tools	NNS	tool
.	SENT	.
</td>
